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Abstract
The research presented here has evolved from the general hypothesis within
our laboratory that DNA in vivo has characteristics which modulate its sensitivity
to DNA damaging compounds. As one component of this overall paradigm, this
work sets out to explore the material and structural properties of DNA that mediate
the targeting of drugs to specific sites within the DNA.
To examine these issues, we have studied the clinically relevant antitumor
antibiotic calicheamicin. Calicheamicin binds DNA non-covalently in the minor
groove and abstracts hydrogen atoms from both sugar phosphate backbones causing
site-specific double-stranded DNA damage. The reactivity of the drug is affected by
both the topology and sequence context of the binding site, suggesting that
calicheamicin recognizes some form of structural perturbation rather than sequence
per se. However, the true mechanism for calicheamicin target selection is
unknown.
To investigate the role of both calicheamicin structure and DNA structure
and dynamics in target recognition, two approaches were taken: First, gel mobility
studies were performed to evaluate whether calicheamicin binding sites possessed a
common element of curvature. Second, DNA cyclization experiments were
conducted to assess and measure the structural changes that occur in DNA when
calicheamicin or its oligosaccharide binds. (Novel modifications were introduced to
facilitate the rapid detection and analysis of DNA bending.) Our results show that
calicheamicin binding sites are not curved, but that both the drug and
oligosaccharide bend DNA upon binding. These data support a model for
calicheamicin target selection where the drug prefers to bind those sequences that
can be easily bent (i.e., flexible) into a conformation that maximizes its electrostatic
and hydrophobic interactions with DNA.
In addition to these experiments, we exploited calicheamicins' ability to bend
DNA to study the affect of topology on the kinetics of DNA bimolecular association.
We show, that when the ends of the DNA molecule are in close proximity,
intermolecular reactions are inhibited; a result that calls into question indirect
methods for measuring bimolecular association reaction rates.
These results contribute to our understanding of small molecule-DNA
interactions and lay the groundwork for understanding how molecules select
genomic targets.
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Prologue
Seminal to the research presented in this dissertation, is the view that DNA is
a structure whose material and conformational properties play a role in regulating
the intracellular environment. Within this paradigm, two hypotheses have
emerged:
First, the degeneracy in the genetic code suggests that structurally different
sequences can be used -- interchangeably -- to code for the same protein. In other
words, while coding for the same gene product, the sequence -- by virtue of its
intrinsic material and topological properties -- can use structure and dynamics to
interact uniquely with its environment.
Second, as an anisotropic structure, DNA contains discontinuities in its
material properties that lead to localized regions of high stress when the molecule
undergoes dynamic motion. On an atomic level, this stress results in an increase in
the reactivity of specific bonds within the structure. We call these hyper-reactive
regions "hot spots".
The importance of these observations is the suggestion that there is more to
DNA than first meets the eye and that to properly understand its behavior, we must
discover and accept what it means to be a structure built from nucleotide bricks.
Indeed, it is from this exploration of DNA structure that this thesis emerges.
CHAPTER I
Introduction
Deoxyribonucleic acid (DNA) is a molecule composed of two complementary
polynucleotide chains twisted about each other in the form of a regular right-
handed helix. The type and order of nucleotides within the chain directs the
construction and function of cellular components necessary to sustain "life." If
damage should occur to the DNA, the instructions may become modified or lost. In
a healthy individuals, such alterations may result in physiological changes that can
cause sickness or death. However, in unhealthy people, we may actually want to
damage cellular DNA intentionally to selectively kill and destroy cells that are part
of, or promote, a diseased state.
In addition to the "genetic code," the sequence of nucleotides in DNA creates
series of uniquely charged chemical surfaces within the grooves of the double-helix
that can act as recognition sites for proteins and other molecules. These regions play
an important role in the proper functioning of the cell by regulating critical
processes such as gene expression and DNA packaging. They also contribute to the
targeting of DNA damaging compounds to specific regions within the molecule.
However, DNA is more than a collection of chemical charges. As a polynucleotide
chain, DNA possesses both material and structural properties that can also provide
unique features that contribute to the recognition of specific sequences by DNA-
reactive chemicals.
The research presented here has evolved from the general hypothesis within
our laboratory that DNA in vivo has characteristics that modulate its sensitivity to
DNA damaging compounds. These include phenomena that affect DNA generally
-- such as chromatin packaging, DNA transcription and supercoiling -- and locally --
as in sequence-defined bending or flexibility. As one component of this overall
paradigm, this work sets out to explore the material and structural properties of
DNA that mediate the targeting of drugs to specific sites within the molecule.
To examine these issues, I have chosen to study the antitumor antibiotic
calicheamicin and its interactions with DNA. Calicheamicin is a clinically relevant
[1, 2], extremely toxic [3, 4] chemical that binds non-covalently to the minor groove
of DNA causing site-specific strand cleavage. My goals were to 1) determine
whether the structural or dynamic properties intrinsic to specific DNA sequences
were responsible for the sequence selectivity of calicheamicin-induced DNA
damage, and 2) discover what, if any, components of calicheamicin were responsible
for these interactions.
This work is significant for several reasons. First, by defining -- at the local
level -- the structural properties that govern DNA binding by calicheamicin, we can
begin to interpret differences in drug-induced DNA damage that are observed under
physiologically relevant conditions in whole cells. In addition, since calicheamicin
targets a wide variety of sequences, we may uncover a common structural motif
unique to specific DNA sequences that increases their susceptibility to damage by
certain compounds. Next, by developing an assay for quickly measuring and
quantifying the effects of calicheamicin binding on DNA structure, we further the
techniques available for the study of similar DNA distorting phenomena. This is
particularly significant given the extreme hydrophobicity and weak binding affinity
of calicheamicin for DNA. And last, by rigorously examining the empirically
observed results from carefully designed cyclization experiments, it may ultimately
be possible to refine theoretical models of DNA structure and to extract --
biochemically -- the topological changes that occur in DNA as a result of drug
binding. In all cases, the research adds to the growing body of data that may one day
allow us to design drugs that target sequence-defined structural or dynamic
properties rather than sequence per se. It will, perhaps, allow us to better
understand why specific drugs target certain areas within the genome and, at the
same time, begin to decipher this secondary "language" of DNA structure and
dynamics.
Calicheamicin
Calicheamicin, a member of the enediyne family of antitumor antibiotics,
has received significant attention both for its potency as a cytotoxic agent [5, 6] and
for the chemistry of its DNA damage [7, 8]. Isolated from Micromonospora
echinospora ssp calichensis, the antibiotic has demonstrated as much as a 1000-fold
greater activity against someiumors than other similar compounds such as
adriamycin [6]. Shown below, the drug consists of a reactive enediyne core
(common to enediyne antitumor antibiotics) attached to a five membered
oligosaccharide chain (aryltetrasaccharide).
0 0
Aglycone NH OCH3
CH SSS H
CH 3  O
3 CH 0 O NH-CH 2CH3
CH 3 C CH3 NH OH OCH 3
HO 0" 7-
C o -OCH 30 _r , Ethylamino
OH Thiosugar amino sugar
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Calicheamicin 71Y
Aside from its practical relevance as a tumor fighting agent, the benefit in
using calicheamicin as a model compound for investigating the interactions of DNA
and drug structure, is that it represents one member of a group of functionally
similar, yet structurally diverse, enediyne compounds. This allows us to investigate
DNA-drug interactions by comparing and contrasting the effects of drug structure on
the affinity and reactivity of these compounds with DNA under a variety of
functional and topological settings [9-12].
Calicheamicin and DNA
Like other members of the enediyne family, calicheamicin produces DNA
damage via a diradical intermediate that, when positioned in the minor groove,
abstracts deoxyribose hydrogen atoms from the DNA backbone (see figure below).
The drug is activated by reduction of the trisulfide moiety which initiates formation
of a relatively stable dihydrothiophene intermediate [13]. The activated drug,
positioned in the minor groove of DNA, then begins a Bergman-type
cycloaromatization to the highly reactive diradical species which then abstracts
hydrogen atoms from the deoxyribose sugars [7, 8]. As a result, the diradical
intermediate is reduced to its inactive form, calicheamicin e, and the oxidized sugar
radicals undergo oxygen-dependent reactions to form abasic sites or strand breaks
[14].
0
SRA R 0
R R R
HO, R HO DNA HOW
H OR HOR HOR  *"OR H
RS- SSCH 3
thiol activation dihydrothiophene diradical intermediate CAL-E
of CAL intermediate
Single molecules of calicheamicin produce predominantly double-stranded
DNA lesions with damage in each strand staggered by two base pairs (bp) [6, 7, 15, 16].
The oxidative damage to the deoxyribose results in products that are specific to the
position of the abstracted hydrogen atoms and are detectable in gel-shift mobility
assays [17-21]. These experiments, combined with deuterium transfer studies, have
shown that hydrogen abstraction occurs in the deoxyribose sugars at the 4' and 5'
positions [13, 22]; the latter, as shown below, positioned three base pairs in a 3'-
direction on the complementary strand.
aglycone 5'-hydrogen abstracted
5 ' XAyi  3'
minor
groove
3'X X X Pu Pu Pu Pu X X 5'
4'-hydrogen abstracted
These results are consistent with hydroxyl radical footprinting and NMR solution
structures of the calicheamicin-DNA complex which suggest that the drug binds
DNA such that the aglycone warhead spans the minor groove with the ethylamino
sugar reaching over the phosphate backbone and the carbohydrate tail adopting a
right-handed screw conformation that extends down the minor groove in a 3'-
direction [22-27].
Calicheamicin damages DNA site-specifically; showing a general preference
for a wide variety of tetrapurine sequences such as AGGA, AGAG, AGGT, TGGA,
AGGC, GAGA and AAAA [6, 7, 28, 29]. This targeting may reflect differences in
binding affinity, if every drug molecule bound leads to a measured damage event; or
in reactivity, if the binding site sequence plays a role in the activation of the drug to
the diradical intermediate or in the rate of the formation of the final damage
products. Most likely, DNA targeting involves some combination of both. In the
case of calicheamicin, it is now generally accepted that the apparent tetrapurine
sequence selectivity reflects a recognition of sequence-dependent local DNA
conformation and dynamics rather than a direct reading of specific base sequences or
issues of reactivity [6, 24-27, 30-37].
The oligosaccharide tail of calicheamicin appears to be the structure
responsible for the sequence selectivity. Damage studies with derivatives of
calicheamicin have shown that the molecule retains site specificity without the
ethylamino or rhamnose sugars, but requires the remaining elements of the
oligosaccharide tail for sequence recognition [38]. The aglycone alone, or with the
hydroxyl amino and ethylamino sugars, is not sequence specific; it binds and
damages DNA indiscriminately with significantly lower affinity [35]. Interestingly,
hydroxyl radical footprinting experiments demonstrate that the oligosaccharide does
not bind in the exact same location as the parent calicheamicin but is instead shifted
slightly [34, 38]. Taken together, these results suggest that the affinity of
calicheamicin for specific DNA sequences is primarily a function of the
oligosaccharide tail with some "small," as yet unknown, contribution from the
aglycone.
How the aryltetrasaccharide recognizes DNA sequence is unclear. In target
sequences with a 5' penultimate cytidine, it has been shown that the presence of the
exocyclic amine from the complementary guanosine (located in the minor groove)
is important to, but not necessary for, recognition [34, 39]. Indeed, molecular
dynamics studies suggest that the thiobenzoate ring changes its orientation
completely when binding to DNA without such an amine present [40]. However,
despite these observations, no pattern of bonding interactions appears to account for
the ability of calicheamicin to uniquely recognize the wide variety of purine
sequences it does.
Several observations suggest that calicheamicin targeting may reflect the
ability of specific sequences to undergo structural changes in response to drug
binding. NMR studies indicate that the relatively rigid carbohydrate side chain
contacts the pyrimidine strand and that the minor groove widens to accommodate
the aglycone [26, 27, 39]. Additionally, observations have been made that
calicheamicin binding causes DNA overwinding and increases the negative
superhelical content of DNA [41, 42]. These data, combined with experiments that
show base changes outside the target recognition sequence affects calicheamicin-
induced damage [38], suggest that DNA topology and dynamics is influenced by
calicheamicin binding. As a result, it may be energetically favorable for
calicheamicin to bind those sequences that can undergo these changes most easily.
As yet, however, there is no unified model for the calicheamicin target recognition
process.
Recent work within the Dedon laboratory has contributed significantly to
resolving many of these issues. In a comparison of calicheamicin-induced damage
in naked DNA to DNA reconstituted into nucleosomes we found that: 1) bending of
nucleosome DNA increased drug-induced cleavage at one site; 2) there is little
correlation between minor groove width per se and calicheamicin target selection;
and 3) calicheamicin appears to recognize the structural discontinuity at the 3'-ends
of purine tracts [43].
The observation that bending could influence DNA damage suggested that
calicheamicin may have a preference for curved DNA; DNA that could
accommodate drug structure with a smaller expenditure of energy. This is
consistent with previous observations that calicheamicin binding caused some,
albeit small, modifications to DNA structure and that some form of an "induced fit"
was responsible for drug binding.
Together, the last two observations suggest the existence of a structural
feature, common to the 3' ends of purine tracts, that increases the susceptibility of
DNA to damage by calicheamicin. This finding is further supported by a review of
the literature which shows that many of the most reactive sites occur at the 3' ends
of purine tracts, as shown below.
CACAAGGGGAGGAAAAGTCAGCCTT Yu et al, GCAGGAGMGCATAAGGGAGAGC1 Nicolaou et al.,
GTGTTCCCCTCCTTTTCATCGGAA Bioorg. Med. Chlem. CGTCCTCAGCGTATTCCCTCTCGC J. Am. Che. Soc.
A A CG 3: 729, 1995 ,A 114: 7555, 1992
' 4 Mah et al., Myers et al.ACCGCAAAAAAAAAAAAAAACCCGC Tetrahedron CGTTGCAGCAAGAGGATCAGCGTGC 
. Cer. Soc.TGGCGTTTTTTTTTTTTTTTTGGGCG 50: 4 GCAACGTCGTTCTCCTAGTCGCACGA44AAM 4 50: 1361, 1994 A 116: 125, 1994
Mah et al. came to a similar conclusion in their work [24]. They propose that the 3'
end of the A-tract is curved, creating a structure which deviates from canonical B-
DNA making it a better target for calicheamicin.
These observations suggest a new model for calicheamicin's interaction with
its DNA targets [43]. Within this paradigm, the drug does not recognize sequence
per se. Instead, a sequence-dependent structural perturbation (i.e., a bend or hinge),
lying 3' to the purine tract at or beyond the purine-pyrimidine junction, facilitates
the reaction of the drug with DNA. It is further suggested that the aglycone plays
some role in the recognition of these DNA features. This is somewhat analogous to
observations of anthramycin and tomaymycin binding to, and bending, target DNA
sequences [44].
To investigate the appropriateness of this model, experiments were
performed to:
1) Identify, if any, the intrinsic characteristics of calicheamicin binding sites
(Chapter II).
2) Qualitatively determine the effects of calicheamicin and oligosaccharide
binding on DNA structure (Chapter III).
3) Quantitatively measure the effect of calicheamicin and oligosaccharide
binding on the kinetics of DNA cyclization (Chapter IV).
To accomplish these objectives, it was necessary to develop techniques to
measure the changes in DNA structure under conditions which allowed the drug to
bind the DNA.
Measuring the Cyclization Properties of DNA
Three methods are most often used to detect DNA curvature or bending:1
electron microscopy, gel electrophoresis and circularization of DNA molecules [45].
The first, electron microscopy, is useful for observing macroscopic structural
phenomena that can be captured and visualized within the operating conditions of
the microscope. Typical results have been estimates of large bend angles or
population profiles, reflecting the proportion of molecules captured in a curved or
1 Curvature is a change in the direction of the helical axis that is sequence defined. In other words, a
property intrinsic to the DNA. Bending is a change in the direction of the helical axis due to external
forces, such as protein or drug binding.
bent conformation [46]. Small changes, however, are often undetectable. Gel
electrophoresis methods take advantage of the abnormally slow migration rate that
macroscopically curved or bent DNA molecules exhibit when compared with
"straight" DNA [47]. The technique is versatile and reliable, in some cases allowing
-- with the proper experimental design -- the estimate of bend angles, the direction
of curvature/bending and even, under some circumstances, changes in twist and
flexibility [48-50]. Unfortunately, the electrophoretic properties of a DNA molecule
are relatively insensitive to small changes in curvature and non-planar superhelical
conformations [51]. Furthermore, it is unclear how flexibility and twist affect gel
migration. As a result, it is often difficult to ascribe specific changes in
electrophoretic mobility to a unique structural or dynamic change in the DNA
molecule.
The T4 DNA ligase-catalyzed cyclization assay, originally described by Shore et
al. [52], has become the most sensitive method for measuring the static and dynamic
properties of a DNA molecule [53]. Under the proper conditions, both bend and
twist changes can be identified and quantitatively defined. The extreme sensitivity
of this technique derives from the conditions required for a DNA molecule to
circularize. To successfully ligate into a circle, a DNA molecule must:
* have ends that are in close proximity to one another,
* have helical axes that are nearly aligned at the ends, and
* be torsionally aligned such that the helical backbone is continuous at the
site of the newly formed bond.
Changes in the first two, due to planar curvature, bending or anisotropic flexibility;2
or the third, as a result of over- or under-winding and torsional stiffness,
dramatically affect the overall rate of cyclization.
Cyclization experiments are often conducted in one of two ways. The first
allows a DNA molecule, with self-complementary ends, to self-ligate and form
either circles or polymers [54, 55]. The process is allowed to continue for long a
period of time after which the circular and linear products are separated by two-
dimensional gel electrophoresis. For each polymer size, the ratio of circles to linear
2 Isotropic flexibility implies that the stiffness of the molecule is the same in all directions. An
example would be a round broom handle. Anisotropic flexibility means that the stiffness properties are
dependent upon the direction that the molecule is being bent. A flat plastic ruler, easily bent across the
thickness but almost impossible to bend across the width, is an example of an anisotropically flexible
structure.
products gives a qualitative measure of the probability of cyclization. The change in
this ratio over the entire range of polymer sizes gives a relative measure of the
cyclization properties of the DNA molecule with respect to other similarly
constructed and tested DNA molecules. The method has several disadvantages.
Since the measured linear products do not faithfully represent the amount of a
specific size polymer that was, or was not, a substrate for further polymerization; no
kinetic information, concerning the rates of cyclization or dimerization, can be
obtained. In addition, it is not clear how, or if, these observations can be analyzed in
a quantitative fashion to reveal the underlying characteristics of the DNA or the
response of DNA to external forces. In Chapter III, an approach is developed to
overcome these difficulties and this assay is used to qualitatively examine the effects
of calicheamicin binding on DNA structure.
The second form of the circularization assay consists of a time course
experiment in which a single DNA molecule is ligated under conditions which
allow either circularization, dimerization or both to occur but limits further
polymerization [56, 57]. The reaction is performed over a short period of time so
that all the reaction products, and their relative proportions, can be identified and
measured. As described in detail in Chapter IV, this allows the individual reaction
kinetics to be determined and the probability of cyclization to be calculated for a
specific DNA molecule under defined conditions.
The relationship between the probability of cyclization and changes in DNA
trajectory or twist for a given molecule have been worked out using statistical
mechanics and polymer chain theory [58]. Monte Carlo simulations have been used
to extract twist and bend data from empirical determinations of the probability of
cyclization over a range of conditions [56, 59, 60]. Therefore, with the proper
experimental approach, it may be possible to precisely determine the structural
changes occurring within a DNA molecule biochemically.
Fundamental to many of these calculations, is the assumption that the rate of
bimolecular association is independent of the rate of cyclization [52]. In other words,
if a DNA molecule is highly curved and cyclizes easily, the rate of bimolecular
association is assumed to be the same as if it were a "straight" DNA that had little, or
no, propensity to circularize. In performing these experiments, we observed that
this may not be the case. In Chapter V, additional experiments are performed to
determine whether DNA length and topology can affect intramolecular reactions.
Regardless, by conducting experiments in which we incrementally change -- by the
addition of drug -- the structural or dynamic characteristic of the same DNA
molecule, we will establish a benchmark for the validation of theoretical models
predicting the dynamic behavior of DNA.
CHAPTER II
The Intrinsic Properties of Calicheamicin Binding Sites
As discussed Chapter I, there is evidence to suggest that calicheamicin targets
DNA sequences that.possess some form of a structural perturbation. In other words,
is it possible that the drug has an affinity for a topological characteristic unique to
specific DNA sequences. Since the nucleosome studies described in Chapter I
indicate that calicheamicin-induced DNA damage is sensitive to DNA bending, it
may be that the drug targets regions of DNA that are intrinsically curved. To test
this hypothesis, an experiment was designed to qualitatively assess whether
different calicheamicin binding sites possessed similar curvatures. While it may be
important in some cases, the results shown here demonstrate that DNA curvature
is not a necessary perquisite for calicheamicin binding.
Experimental Design
To determine whether calicheamicin binding sites are -- as a group --
intrinsically curved, we examined the migration of DNA polymers containing two
different, but phased, calicheamicin binding sites on non-denaturing polyacrylamide
gels. The studies are premised upon the anomalously slow migration of curved
DNA sequences when compared to "straight" DNA of the same size [45, 47-50, 61,
62]. This behavior is thought to arise from the fact that a rigid, curved molecule has
a larger enclosed volume or surface area which excludes gel fibers. This interferes
with the ability of the curved DNA to reptate smoothly. In general, the greater the
enclosed area the slower the DNA migrates. Therefore, long DNA molecules will
migrate much more slowly than short molecules with an identical radius of
curvature. As a result, small DNA bends can often be detected by repeating the bent
sequences in-phase with the helical repeat of canonical DNA (10.5 bp) such that all
the bends occur in the same direction to form a longer DNA molecule with an
observable degree of planar curvature.
To establish that any electrophoretic anomaly was the result of curvature at
the calicheamicin binding sites, three duplex oligonucleotides were tested. The "in-
phase" DNA construct, shown below, contained two calicheamicin binding sites,
AGGA*TCCT [7] and ACAA*TTGT [35], spaced 10 base-pairs (bp) apart in a 21 bp
DNA duplex.
GTGCGA CCT ATC TT
GCTAQGG ATAGCAACACAC
I<- 10bp -- 1
in-phase construct
These sequences have been shown to be high affinity binding sites for both
calicheamicins 711 and E [33, 35]. At each site, the purine-rich sequence was
positioned on the same strand to ensure that the aglycone portion of the drug
molecule was at the 3' end with the oligosaccharide tail extending in the 5' direction
across the recognition site [22, 23, 33]. When self-ligated, the 21 bp DNA monomer
would form polymers with binding sites aligned -- on average -- with the 10-5 bp
helical repeat of B-DNA. Since all the binding sites in the polymer were in-phase
with each other, any small localized sequence-dependent curvature would add
constructively, effectively magnifying a small localized bend into a planar
macroscopic curve observable by polyacrylamide gel electrophoresis.
The three base pair CAC*GAG complementary ends of the DNA oligomers
were designed to allow the cloning and preparation of large quantities of purified
polymers. No other combination of two or three base pairs would allow integration
of the polymer into a standard cloning vector without introducing an additional.
calicheamicin binding site at the junction between two monomers formed during
self-ligation.
To verify the dependence of any observed DNA curvature on the
calicheamicin binding sites, two additional constructs were tested. The "out-of-
GTGATCGATCCT TCPTT GA
GCTCTGG-AGLAAL TCAC
-1 8 bp 4-
out-of-phase construct
phase " 21 bp duplex oligonucleotide has the same binding site sequences as the in-
phase monomer except that they are now spaced 8 bp apart. If the calicheamicin
binding sites were curved, then polymers formed from the self-ligation of this
construct would form a 3-dimensional zig-zag or superhelical structure which
would migrate more like "straight" DNA than the planar curved generated from the
in-phase polymers.
GTGCGATPT CTATC Cf ACTA
GCTALC GATAGCTGATCAC
1--0 bp -->
no-site construct
The "no-site" construct contains the same sequence as the in-phase DNA duplex
except that the calicheamicin binding sites have been abolished by exchanging the
central two base pairs on opposite strands. If polymers created by the self-ligation of
this construct migrate normally, then any observed anomaly with the in-phase
monomer must be the result of the intact calicheamicin binding sites and not
curvature arising from adjacent sequences. (This is necessary since all the sequences
are repeated every 21 bp and are therefore in-phase with each other.)
Two additional duplex oligomers served as positive and negative controls.
When self-ligated, the A-tract monomer forms curved polymers that exhibit
anomalous migratory behavior on polyacrylamide gels [54]. Conversely, polymers of
the 10 bp BamH I linker DNA have been used historically as a benchmark for
"straight" DNA in gel mobility assays [49].
TCTC TA AAA TAT I  CGGGATCCCG
TTTTTTATATTTTTTAGAGA GCCCTAGGGC
A-tract BamH I linker
To verify that each of the above constructs contained the desired
calicheamicin binding sites, damage studies were performed using calicheamicin Y1I
on restriction fragments from cloned vectors containing polymers of the DNA
monomer constructs.
Materials and Methods
Synthesis and purification of DNA oligonucleotides. DNA oligomers were either
synthesized (391 DNA synthesizer from Applied Biosystems, all reagents from
Biogenex) or purchased from Oligo's Etc. (Portland, OR). Synthesized oligomers (2
pmoles) were deprotected by an overnight incubation at 55°C in 1 ml of ammonium
hydroxide, lyophilized and resuspended in 500 ml of water. All oligomers were
purified by gel elution from 20% polyacrylamide sequencing gels [63] and desalted
using C18 Sep Pack cartridges (Waters).
Construction of the pAS1 cloning vector. Plasmids containing DNA polymers of
multiple monomer units were created by inserting polymers into a modified pUC19
cloning vector and transfecting the vector into a non-methylating E. coli host for
culture. To modify the pUC19 vector for this purpose, the native Sap I site at 683
was removed by digesting pUC19 with Tfi I, gel purifying the larger DNA fragment
and religating the vector (pUC19-Sap). The pUC19-Sap was prepared to accept the
polymer constructs by inserting a new Sap I restriction site at the BamH I site of the
polylinker region as shown in Figure 2.1. The 24 bp insert contained a Sap I
recognition element that would leave, after digestion, a GTG overhang at the 3' end
and a CAC overhang on the 5' end. Since the insert was small and reading frame
maintained, the ability of the new vector, pAS1, to u-complement was preserved.
Construction of pAS1/nmx plasmids. A family of clones containing the same
monomer element "x" repeated "n" times was created by digesting pAS1 with Sap I,
dephosphorylating the vector, and ligating in either gel purified polymers of a
specific size or a mixture of polymers resulting from the self-ligation of monomers.
The ligation was performed at micromolar duplex monomer concentrations for 4
minutes at 0°C to prevent further polymerization or cyclization of the polymers.
The mixture of polymers was then ligated into Sap I-digested pAS1 at a molar ratio
of 50:1, vector to polymer. GM2163 E. coli cells were transformed with the resulting
vectors and the individual clones characterized by plasmid minipreps, DNA
sequencing and gel electrophoresis [63, 64]. Particularly useful in this process was the
modified mini-prep protocol developed by Lee and Suraiya [65]. The GM2163 strain
was chosen since it is dam methylase deficient and can undergo (-complementation
(NEB). Each clone was characterized by the type and size of the polymer insert. For
example, a pAS1 vector containing a polymer of 12 repeated monomer elements of
the in-phase DNA duplex was named pAS1/12m9 (9 for in-phase, 10 for out-of-
phase and 11 for no-site constructs). For larger quantities, plasmids containing the
desired insert were grown under appropriate conditions for the host GM2163 cells
(NEB fact sheet #316) with chloramphenicol to increase copy number and reduce
contamination by genomic DNA [63]. Plasmid DNA was then extracted and purified
using Qiagen Giga Preps.
Identification of calicheamicin binding sites. To verify the location of calicheamicin
binding sites, specific cloned DNA constructs (i.e., pAS1/5m9, pAS1/6m10 and
pAS1/3m11) were digested with EcoR I, 5'-[ 32p] end-labeled with T4 polynucleotide
kinase and 7-[32P]-ATP, purified on G25 Quick-spin Columns (Boehringer), and
digested with Hind III [63]. The labeled fragment containing the insert was purified
by elution from a 10% polyacrylamide gel [63]. Damage reactions consisted of labeled
DNA (-50,000 cpm), 30 jgg/ml of calf thymus DNA, calicheamicin Y11 (0-30 nM), 1%
methanol, 10 mM glutathione, 50 mM HEPES, 1 mM EDTA, pH 7. The reaction was
initiated by adding calicheamicin. After 1 hr at O'C, the DNA was purified and
resolved on an 8% sequencing gel.
Gel mobility assay. The electrophoretic migration studies on the DNA constructs
were conducted as follows. Monomers were 5'-[ 32p] end-labeled and ligated with T4
DNA ligase in a reaction containing 7-5 mM labeled monomer, 50 mM Tris-HCl (pH
7.8), 10 mM MgC12, 10 mM dithiothreitol, 1 mM ATP and 50 gg/ml bovine serum
albumin. Ligase was added to a final concentration of 8 units/ml and the mixture
was incubated overnight at 160C. The DNA was extracted once with
phenol/chloroform, precipitated in ethanol, and resolved by electrophoresis on an
8% non-denaturing polyacrylamide gel. Gels were then dried and subject to
autoradiography or phosphorimager analysis (Molecular Dynamics).
Results and Discussion
Synthesis, cloning and purification of DNA constructs. In general, the cloning
strategy worked well and a variety of plasmids containing different sized polymers
of the three monomer inserts were created. Transformed cells showed a propensity
for removing whole monomers from the polymer chain, converting from a
pAS1/nmx to a pAS1/(n-1,2...)mx when cultured in large quantities. In some cases,
the vector would loose the entire insert. E. coli strains deficient in a variety of
recombinant proteins fared worse that the GM2163 strain. In any case, the presence
of multiple polymer sizes within a recovered plasmid sample had no effect on the
damage assays.
Calicheamicin damage in DNA constructs. To ensure that the DNA constructs
possessed the predicted binding sites, multimers of each monomer were damaged by
calicheamicin 711 and the cleavage products analyzed on sequencing gels. As shown
in Figure 2.2, the mixed-site polymers were damaged only at the expected sites.
Consistent with previous studies, damage at the AGGA site occurred more
frequently than the ACAA site [24, 35]. The absence of a similar damage pattern in
the no-site construct, under the same conditions, indicates that the primary binding
sites have been abolished by the change in sequence. However, a closer look at
Figure 2.2 does show the presence of one, perhaps two, low affinity binding sites at
different locations.
If we assume that the frequency of drug-induced damage reflects the binding
affinity of calicheamicin for these sequences then the drug binds the DNA oligomers
as designed.
Calicheamicin binding sites are not intrinsically curved. To determine whether
calicheamicin binding sites possessed any intrinsic curvature, each monomer was
5'-end labeled, self-ligated and resolved on an 8% non-denaturing polyacrylamide
gel. From Figure 2.3, it appears that the binding site constructs migrated normally
with respect to the BamH I linker. As expected, the curved A-tract migrated much
slower than similarly sized DNA in the adjacent lanes.
The mobility of these polymers relative to the BamH I linker DNA can be
quantitatively expressed as the ratio of the polymers apparent length to its true
length (RL). The apparent length is determined by measuring the migration
distance of a specific DNA polymer and determining the length of "straight" DNA
that would migrate the same distance. The following equation, describing the
migration behavior of "straight" DNA, was derived empirically by finding the best
fit to the BamH I Linker data (R2 > 0-995, see Figure 2.4; least squares analysis
performed in Cricket Graph by Cricket Software).
ln(X) = 6.41 + 0-29 ln(MW) (2.1)
where X is the migration distance in centimeters and MW is the molecular weight
of the polymer. Rearranging and assuming the molecular weight of each base pair is
650g/mole, gives the following equation for the apparent length (in base pairs) of a
DNA polymer migrating X (cm) on the gel:
ALbp = (6.13 x 106) X-3-45  (2.2)
Dividing equation 2.2 by the true length of the polymer, gives the RL value for that
specific DNA molecule. The RL values for the polymers shown in Figure 2.3 are
plotted in Figure 2.5.
None of the binding site constructs exhibited significant migration anomalies
relative to a "straight" DNA standard [66]. These results stand in striking contrast to
the abnormally slow migration of the A-tract. These data suggest that neither in-
phase, out-of-phase or no-site constructs possess a significant degree of intrinsic
curvature. This does not, however, rule out the possibility that calicheamicin
targets curved or bent DNA. Therefore, it can only be concluded that two of the
DNA sequences recognized by calicheamicin are not curved and that DNA
curvature is not necessary for calicheamicin binding. It is important to note that
these results do not preclude the possibility that other sequence dependent
properties such as flexibility or twist are responsible for calicheamicin target
recognition.
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Figure 2.2. Damage produced by calicheamicin Y11 in the binding site constructs.
Cloned polymers of each monomer were end-labeled, treated with calicheamicin Y11
(0-30 nM) and resolved on sequencing gels. Sequence diagrams, indicating the
location of the damage sites in each of the constructs are shown to the right.
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CHAPTER III
The Effects of Calicheamicin Binding on DNA Topology
DNA is a chain-like structure whose mechanical properties are governed by
the hydrophobic and electrostatic forces acting between its individual elements. The
balance of these forces determines the overall trajectory, or shape, of the molecule
while their interaction defines how the structure will respond to its external
environment. In other words, like a solid bar, DNA has properties of form (i.e.,
curvature and twist) and function (i.e., lateral and torsional stiffness).
As discussed in Chapter I, there is evidence to suggest that calicheamicin
selects its targets based -- at least in part -- on the topological characteristics of the
binding site. In Chapter II, however, data were presented to show that DNA
sequences bound by calicheamicin are not necessarily curved. To 1) explore this
apparent inconsistency and 2) further understand the role of DNA flexibility in the
target selection process, experiments were performed to investigate the changes that
occur in DNA structure when calicheamicin binds. By finding what, if any,
topological changes occur when the drug binds, we may be able to infer the sequence
dependent properties that facilitate drug binding.
Experimental Design
As described in Chapter I, the biochemical methods for looking at DNA
structure are rather limited. Measuring the changes in electrophoretic mobility of
drug bound DNA can reveal drug-induced changes in DNA structure. However,
the extreme hydrophobicity and weak binding affinity of calicheamicin for DNA
make this approach difficult. The T4 ligase DNA cyclization assay, described in
Chapter I, overcomes these problems and provides greater detection of drug-induced
structural changes. The assay can be run under a wide variety of conditions and,
because it relies on circle closure, is much more sensitive to bend and twist changes.
To determine whether a particular sequence is curved, bent or anisotropically
flexible by DNA circularization, the sequence of interest is repeated in-phase with
the helical repeat of B-DNA and the probability of the molecule forming a circle
measured with respect to a random sequence DNA molecule of the same length.
The propensity of these DNA molecules to form circles is then measured by
"trapping" transiently cyclized products with T4 DNA ligase to form covalently
closed circles which can then be separated from uncircularized reaction products [49,
52, 54, 57]. (The ends are "transiently" joined by non-covalently hydrogen bonding
between complementary bases.) The proper phasing of the binding sites ensures
that the structural changes at each site add constructively to magnify their
individual effects. If the in-phase binding sites are bent, then the DNA molecule
will curve in a plane and the ends will move closer together, thus increasing the
probability of non-covalent binding of the ends and therefore, the number of
covalently closed circles.
As discussed in Chapter I, factors other than bending can affect the rate of
circle formation. They are:
1) Molecule length - Longer molecules possess greater intrinsic flexibility
making it easier to bring the ends close together.
2) End sequence - Both the length and sequence of the complementary ends
affect the association and disassociation rates of non-covalently closed
DNA circles. Longer, or G*C rich, sequences promote non-covalent
binding over shorter, or A*T rich, sequences.
3) End Alignment - When the phosphate backbones are aligned, hydrogen
bonding occurs easily and facilitates covalent closure. Ends out-of-phase
by ninety degrees hydrogen bond with much lower frequency and
therefore, form fewer circles. This is not the case for long pieces of DNA
(approximately 250 bp and larger) where an accumulation of torsional
flexibility throughout the chain effectively decouples the rotational
position of one end from the other. As a result, the sensitivity of DNA
circularization to twist changes within the molecule decreases with
increasing molecule length.
Each of these factors must be considered in both the design and interpretation of
DNA cyclization experiments.
To assess the bend and twist changes that occur in DNA when calicheamicin
binds, circularization studies were performed on the in-phase and out-of-phase
DNA duplexes described in Chapter II. The oligomers were annealed with their
complementary strands, radiolabeled and polymerized with T4 DNA ligase under
conditions that allowed circles to form once the DNA molecules had reached a
reasonable length. Since components of the ligation reaction buffer activated
calicheamicin into the DNA-damaging diradical species, the experiments were
performed with calicheamicin r, an inactive form of the drug. While the two
compounds bind DNA at the same sequences [33], calicheamicin e appears to bind
with 10- to 15-fold lower affinity [67].
NH OCH3
HO \
NH-CH2CH
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calicheamicin E
To assess qualitatively the effects of calicheamicin binding on DNA structure,
circularization experiments were performed with both the in-phase and out-of-
phase DNA constructs over a broad range of drug concentrations. The reactions
were repeated with the oligosaccharide portion of calicheamicin to determine which
component of the parent compound was responsible for any observed effects.
CH 3
CH 30 OCH 3
oligosaccharide (aryltetrasaccharide)
The circular reaction products were resolved by gel electrophoresis using a novel
approach that obviated the need for two-dimensional electrophoresis. Identification
of individual circle sizes was accomplish by recovering and denaturing putative
circular DNA prior to gel electrophoresis.
Seminal to the interpretation of any result, was the assumption that the
relative proportion of calicheamicin binding between the two sites was the same for
both the in-phase and out-of-phase DNA constructs. In other words, did moving
the binding sites closer together, from 10 to 8 bp apart, cause binding at the higher
affinity site to inhibit drug binding at the second site (negative cooperativity). The
damage studies performed in Chapter II with calicheamicin Y11 did not rule out this
possibility since the reactions were carried out under single-hit conditions. To
address this issue, a second series of damage studies were performed with
calicheamicin 0, a calicheamicin analog with a thioacetate trigger instead of a
methyltrisulfide [68].
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With calicheamicin 0, it was possible to measure drug-induced DNA damage over a
broad range of drug concentrations by titering the amount of glutathione activator
so that similar levels of DNA damage were produced, even under saturating
amounts of drug. If the no-cooperativity assumption was false, then at high
calicheamicin concentrations the relative proportion of damage between the two
binding sites would change.
Materials and Methods
Reagents and DNA substrates. Calicheamicins 711 and , were provided by Dr. George
Ellestad (Wyeth Ayerst Research) or synthesized as described below; calicheamicin 0
and the aryltetrasaccharide were provided by Prof. K.C. Nicolaou (Scripps Research
Institute). All enzymes were obtained from New England Biolabs.
Deoxyoligonucleotides were prepared as described in Chapter II.
Synthesis and purification of calicheamicin e. Calicheamicin a was synthesized
using a protocal provided by Dr. George Ellestad (Wyeth Ayerst Research): 1 mg of
calicheamicin 711 in 330 gl EtOH was diluted with 330 tl of 0-5 M Tris-HCl (pH 7-5).
The reaction was initiated by adding 330 gl of 0.5 M methyl thioglycolate (in EtOH)
and stirred at room temperature for 2 hours. The reaction products were separated
by HPLC using a linear gradient of 42-5 mM triethylamine (pH 6-0) in 15%
acetonitrile to 20 mM triethylamine (pH 6-0) in 60% acetonitrile over 25 minutes.
The peaks, shown in Figure 3.1, were collected, lyophilized and resuspended in 100%
MeOH at 400 ptM. Calicheamicin F was verified by TLC and the concentration of the
stock solution was determined by UV absorbance at 280 nm; -280 = 11,536 M-1cm-1
[69].
DNA damage studies with calicheamicin 0. Cloned plasmids for the pAS1/13m11
were prepared as described in Chapter II, digested with Xba I and 5'-[ 32p] end-labeled.
Following digestion with EcoR I, the labeled fragment was purified by elution from
an 8% polyacrylamide gel. Damage reactions consisted of labeled DNA (-30,000
cpm), 30 tg/ml of calf thymus DNA, 10 mM glutathione, 10 mM HEPES, 1 mM
EDTA (pH 7). The reaction was initiated by adding calicheamicin 0 and then
glutathione as follows:
[Calicheamicin 0]final [GSH]final Incubation Time
0.1 gM 10 mM 1 hour
1 gM 10 mM 1 hour
10 iM 1 mM 1.5 hours
100 tM 0 mM overnight
After incubation for the appropriate time at 370C, the DNA was ethanol precipitated
and resolved on a 6% sequencing gel. Bands were quantified by phosphorimager
analysis.
DNA ligation experiments. The labeling and ligation reactions to produce circular
DNA molecules from monomer substrates were performed as follows. Equal
quantities of complementary oligomers were mixed and heated to 75°C and brought
slowly to room temperature. Annealed DNA (1-4 gg) was 5'-end labeled in a 40 gl
reaction with 450 ptCi of y-[32P]-ATP (=6,000 Ci/mmole) and 20 units of T4
polynucleotide kinase (NEB) in standard reaction buffer for 2 hrs at 37°C. The DNA
was extracted with phenol/chloroform and purified on G25 Quick-spin Columns
(Boehringer). The DNA was then quantified by UV absorption.
The ligation reaction was carried out in 50 pl of NEB T4 DNA ligase reaction
buffer with 120 ng of radiolabeled DNA, 4% methanol, the appropriate
concentration of calicheamicin c or oligosaccharide (added in the methanol) and 400
units of T4 DNA ligase at 16°C overnight. The DNA was then extracted with
phenol/chloroform and precipitated in ethanol. The reaction products were
resolved by two- or one-dimensional electrophoresis as described below.
Resolving circular reaction products by two-dimensional gel electrophoresis. Two
dimensional gel electrophoresis was performed to resolve circular DNA products.
The DNA was resolved on an 8% non-denaturing polyacrylamide gel for
approximately 2,700 V-Hrs. The gel was marked and placed for autoradiography so
that the lane with the bands of interest could be located. A 3 cm x 25 cm gel slice,
containing the DNA, was excised and placed at the top of a fresh set of plates. A
second 8% non-denaturing polyacrylamide gel containing 50 gg/ml chloroquine was
cast around the gel slice. The DNA was then run in the second dimension for
approximately 2,700 V-hrs in TBE containing 50 gg/ml chloroquine. The gel was
then dried and subject to autoradiography and/or phosphorimager analysis.
Resolving circular reaction products by one-dimensional gel electrophoresis.
Visualization of circularized DNA products by one-dimensional electrophoresis was
accomplished by first digesting the linear DNA with BAL-31. The DNA ligation
reaction was carried out as described above and the DNA extracted with
phenol/chloroform, precipitated in ethanol and then digested with BAL-31 using 1
unit per 120 ng of duplex DNA substrate for 1 hour at 30'C. The reaction was
stopped by adding EGTA to a final concentration of 20 mM and the DNA extracted
with phenol/chloroform and ethanol precipitated prior to electrophoresis on either
an 6 or 8% non-denaturing polyacrylamide gel.
Verification of DNA circle sizes. The nature and size of the putative circular DNA
was established by denaturing gel electrophoresis. The bands remaining after BAL-
31 digestion were excised, the DNA eluted from the gel slice, denatured by heating at
90'C for 5 minutes and then resolved on an 8% denaturing polyacrylamide gel
containing 6M urea.
Quantitative analysis of reaction products. The ligation products were analyzed by
phosphorimager analysis on a Molecular Dynamics Phosphorimager with
ImageQuant software. The mathematical operations, described below, were
performed in Microsoft Excel (MicroSoft), KaleidaGraph (Abelbeck Software) or
Cricket Graph (Cricket Software).
Results and Discussion
Calicheamicin binding does not inhibit drug binding at adjacent sites. To verify
that calicheamicin binding at one site did not interfere with binding at an adjacent
site, we performed a second series of damage studies with calicheamicin 0, a
calicheamicin analog with a thioacetate trigger instead of a methyltrisulfide [68]. In
addition to activation by glutathione, the thioacetate moiety can undergo hydrolysis
that also leads to a rearrangement of the aglycone to the reactive diradical species
[68]. However, unlike direct activation, spontaneous hydrolysis of calicheamicin 0 is
a slow process when compared to formation of the drug-DNA complex. Therefore,
using calicheamicin 0, it was possible to measure drug-induced DNA damage over a
broad range of drug concentrations by titering the amount of glutathione activator
so that similar levels of DNA damage were produced across a broad range of drug
concentrations. If drug binding at the two closely spaced sites were inhibited, then
we would expect to see a change in the relative proportion of damage occurring at
the two sites at high drug concentrations.
Figure 3.2 shows the damage produced by calicheamicin 0 in the out-of-phase
construct over a broad range of drug concentrations. In the range of drug
concentrations tested (1-100 jiM), the ratio of calicheamicin 0-induced DNA damage
at neighboring binding sites was the same (approximately 3-5:1). Similar data were
obtained for the in-phase DNA (data not shown). These results indicate that, even
at high concentrations, calicheamicin binds without any difference in cooperativity
between the binding sites in the in-phase and out-of-phase constructs. This is
consistent with hydroxyl radical footprinting studies [33], and the calicheamicin Y11
damage studies described in Chapter II, which show that the ratio of damage
between the two sites is the same for the in-phase and out-of-phase substrates.
From these results, we can conclude that calicheamicin binds equally well to
the in-phase and out-of-phase DNA constructs and that negative cooperativity does
not occur at high drug concentrations.
An improved method for the rapid assessment of circular DNA reaction products.
Historically, two-dimensional gel electrophoresis has been the standard technique
for resolving small circular DNA from linear DNA of the same size [54]. The
method requires two gels. The first, is a standard polyacrylamide gel that separates
all the reaction products by molecular weight. After the products are resolved in a
single column, the strip of gel containing the DNA is removed and placed atop a
second gel impregnated with a DNA intercalator such as chloroquine. The
chloroquine supercoils the circular DNA, changing its electrophoretic mobility with
respect to linear DNA of the same size. As a result, the second gel separates the two
reaction products. An example of a two-dimensional polyacrylamide gel is shown
in Figure 3.3.
To resolve circular DNA products formed under a broad range of reaction
conditions would require two gels for each individual drug concentration and
substrate tested; literally, fifty or more gels. Shore et al. [52] have addressed this issue
by using mung bean nuclease to remove the [32P]-labeled overhangs from linear
DNA polymers. Unfortunately, the polymers used here have multiple radioactive
phosphates throughout the linear DNA that are inaccessible to the enzyme.
Crothers suggested using the BAL-31 nuclease to distinguish between circular
and non-circular DNA [53, 70, 71]. BAL-31 is an is an extremely stable enzyme which
degrades both single- and nicked double-stranded DNA. On double-stranded
molecules, the enzyme acts exonucleolytically from both the 3' and 5' ends [72, 73].
Therefore, uncyclized DNA (since it has ends that are accessible to the enzyme) are
digested processively into smaller and smaller pieces. We have developed this
technique by optimizing the reaction conditions so that BAL-31 removes nearly all
the linear polymers. After removing unincorporated nucleotides, the remaining
DNA circles can be resolved by one-dimensional gel electrophoresis.
An example of the T4 ligase/BAL-31 technique applied to the in-phase
calicheamicin binding site oligonucleotide is shown in Figure 3.4. In the absence of
BAL-31 digestion, an intense ladder of linear polymers extends into the region of the
gel containing circular DNA bands. However, BAL-31 digestion resulted in a
reduction of linear DNA fragments by more than 10-fold relative to circles. The
identity of the DNA bands was verified as described in the Materials and Methods
section.
To establish that the population of DNA circles remaining after BAL-31
digestion faithfully reflected the original population, we examined the distribution
of circle sizes as a function of both BAL-31 concentration and digestion time.
Figures 3.5 and 3.6 show the change in products over a range of digestion conditions.
In all cases, the distribution of circle sizes did not change as a function of digestion
time or BAL-31 concentration, even though -- as expected -- the intensity of the
circular DNA bands was reduced in the longer digestions (Figure 3.4).
Our findings suggest that BAL-31 digestion is an effective method for
distinguishing circular from linear DNA. The procedure obviates the need for two
dimensional electrophoresis, allowing multiple samples to be analyzed on one gel.
Calicheamicin E bends DNA. To investigate the effect of calicheamicin binding on
DNA structure, the in-phase DNA construct was polymerized under conditions that
facilitated circle formation. The general conditions for these reactions are
summarized in Table 3.1. After ligation, the DNA was digested with BAL-31 and the
reaction products resolved by one dimensional electrophoresis on eight percent
polyacrylamide (Figure 3.7). Bands corresponding to putative DNA circles were
excised and eluted, denatured, and separating the products by denaturing gel
electrophoresis. When denatured, double stranded circles convert to three products;
catenanes, single stranded circles and linear DNA. Circle identification using this
method is shown in Figure 3.8.
To assess the effect of drug binding, the amount of radioactivity in each band
was quantified by phosphorimager analysis and normalized according to its
corresponding circle size. The percentage of a specific circle size was then calculated
by dividing the normalized radioactivity by the sum of the normalized radioactivity
for all the circles measured. (See Table 3.2 for an example.)
As shown in the gel in Figure 3.7 and graphically in Figure 3.9, the
distribution of circles formed shifts towards smaller circle sizes as drug
concentration is increased. This can be seen more clearly in Figure 3.10, which is a
plot of the mean of the individual circle distributions for two separate cyclization
experiments with the in-phase monomer.
Three factors could account for the observed reduction in mean circle size for
the in-phase construct:
* Binding of calicheamicin to sites in-phase with the helical repeat of B-
DNA may introduce a planar bend, bringing the ends of the polymer closer
together increasing the probability of cyclization.
* Calicheamicin binding may twist the DNA and alter the helical repeat
such that the ends are moved into progressively better alignment as more
and more the drug binds.
* Calicheamicin may act in a sequence independent manner to affect the rate
of cyclization.
To address the last two possibilities, we repeated the cyclization experiment with the
out-of-phase DNA construct. If the second scenario were true, then the out-of-phase
construct would respond identically to the in-phase monomer since the effects of
DNA twisting on the relative position of the ends does not depend on where in the
molecule the twisting occurs. We would also expect the out-of-phase construct to
respond like the in-phase monomer if the drug affected cyclization regardless of
sequence.
The response of the out-of-phase construct to calicheamicin binding is shown
in Figures 3.11 through 3.14. Unlike the in-phase monomer, the out-of-phase
construct shows relatively little reduction in mean circle size as calicheamicin S
concentration increases. In other words, the change in the cyclization properties of
the in-phase construct cannot be attributed -- solely -- to a twisting of the helix or
some other sequence independent phenomena.
The small shift in the mean circle size for the out-of-phase construct may be
the result of different binding affinities between the two sites, incomplete
cancellation of the bend components or some degree of twist. Unfortunately, the
sensitivity of our assay to twist is reduced due to the 3 bp overlap of the
complementary ends in the DNA polymers [53]. However, since a significant
calicheamicin-induced reduction in circle size was apparent only with the in-phase
constructs, we can conclude that the majority of the change observed in the
cyclization properties must be a response to bending and not twisting. Given these
observations, we conclude that DNA is bent in response to calicheamicin E binding.
The oligosaccharide of calicheamicin E bends DNA. The mean circle size assay was
repeated using the in and out-of-phase DNA constructs over a wide range of
oligosaccharide concentrations. The results are shown in Figure 3.15. The mean of
the circle size distributions for both DNA constructs decreases with increasing
oligosaccharide concentrations. The change is greatest for the in-phase construct
which shows a decrease in mean circle size from 10 to 8-5. From these results, we
can conclude that the oligosaccharide binding -- alone -- is sufficient to modify DNA
structure. Whether this change in structure is a bend or twist remains unclear.
Several factors could account for the observed shift in the out-of-phase
construct. First, since the oligosaccharide does not bind at "exactly" the same site as
the parent drug, the shift could result from the oligosaccharide binding the in-phase
construct slightly out-of-phase and the out-of-phase construct partially in-phase.
This would reduce the shift seen in the in-phase construct and increase the shift in
the out-of-phase construct. Second, the oligosaccharide may have a greater affinity
for one binding site over the other. This would reduce oligosaccharide binding at
sites out-of-phase with the high affinity site; thereby increasing the in-phase bending
in the out-of-phase construct. Last, the oligosaccharide may be twisting rather than
bending the DNA. This would mean that the aglycone suppresses this action in the
parent drug and that our assay is sensitive enough to detect these changes. In any
case, the oligosaccharide clearly introduces large structural perturbations into the
DNA structure.
Estimating the degree of calicheamicin-induced DNA bending. Assuming that the
bending stiffness of DNA is independent of the degree of flexure, we can roughly
estimate the amount of calicheamicin-induced DNA bending by comparing the
mean circle size of the bound and unbound DNA monomers.
The bending required to bring the ends of a DNA molecule together to form a
circle can be determined by approximating the shape of the bent DNA polymer as an
"n" sided regular-polygon. This assumes that all the bends are of the same
magnitude and are equally spaced along the chain. From the figure below, the angle
idealized representation
S180 3600 of DNA bent within a circle
a = 1800_ n
enclosed by two sides of a regular-polygon, 3, is equal to
3600
180 -
n
where n represents the number of bends in the perimeter of the polygon. The bend
angle with respect to a local tangent, cc, is 1800 - P. Therefore,[ 3600
a = 180' - [1800 
- (number of bends)_*
As seen in Figures 3.11 and 3.12, even linear, as opposed to bent, DNA will
form circles. The reason is that each base-pair has some freedom to move (i.e.,
flexibility), which allows the molecule to bend in response to external forces. As the
DNA chain lengthens, this intrinsic flexibility accumulates to the point where the
random dynamic motions of the molecule brings the ends of the DNA close enough
together to ligate. This "intrinsic flexibility" of the DNA polymer must be accounted
for to reasonably estimate calicheamicin-induced DNA bending.
Based on the circle sizes observed for the in-phase monomer without
calicheamicin (Figure 3.12), it appears that circles formed are arranged in a Gaussian
distribution whose average behavior is well represented by the mean. If we model
this "mean circle" as a regular-polygon where the circumference equals the
perimeter, and each base-pair represents a bend, then we can calculate the per base-
pair flexibility for the in-phase monomer under our experimental conditions. In
this case,
S= 180 - [180 - numbei circle'ornumber of base-pairs in the mean circle or
1800 3600 ] 3600
S  
- 18 - MCS x 21 (base pairs per monomer) MCS x 21
where af is the average bend angle due to intrinsic flexibility and MCS is the mean
circle size in monomer units. Substituting the mean circle size for the in-phase
monomer without calicheamicin,
3600
af 173 °9-92 x 21
That is, each base-pair can -- on average -- bend 1-73 degrees without calicheamicin.
When the ligated monomers were bound by calicheamicin F the mean circle
size dropped from 9-92 to 7-98. The overall bending experienced by the DNA
polymer is the sum of drug-induced bending and intrinsic flexibility. In other
words,
total bending = 3600 = af x (total number of base pairs)
+ acal x (number of calicheamicin binding sites)
where ccal is the bending that occurs at each drug binding site. Therefore,
360 - (af x total number of base pairs)
acal = (number of calicheamicin binding sites) or
360' - (1.730 x MCS x 21) 3600 - (1-73' x 9-92 x 21)
cal = 2 x MCS 2 x 9-92 = 44
That is, the bending introduced at each calicheamicin F binding site can be estimated
at 4-4 degrees.
This result is probably an overestimate of the actual bend angle since the
original assumption is likely untrue. In fact, the change in the shape of the circle
distributions as the mean circle size decreases, Figure 3.9, suggests that the flexibility
of the DNA becomes more and more anisotropic at small circle sizes. This result
implies a stiffening of the molecule as the DNA becomes more bent. However,
since the DNA molecule has many degrees-of-freedom that may accommodate
conformational changes at relatively no energetic cost, the approximation may be
reasonable over a small range of mean circle sizes and our estimate, not too far off.
A second assumption was that each calicheamicin-induced bend was identical
in location, direction and magnitude. Given the wide variety of sequences
recognized and the unique structural characteristics that each must have, this may
not be the case. It is likely that different sequences respond uniquely to
calicheamicin binding; some may bend a lot, some a little. Regardless, the bend of
4-4 degrees may prove useful in evaluating specific models of calicheamicin binding.
Mathematically modeling the change in mean circle size. The change in the mean
circle size in response to calicheamicin c binding to the in-phase DNA construct
bears a strong resemblance to a standard titration curve. As a result, it may be
possible to extract quantitative data about the drug-DNA binding relationship.
Assuming that calicheamicin-DNA binding can be described by
ka
[B] + [CAL] - [B-CAL]
where [B] is the concentration of binding sites, [CAL] the concentration of
calicheamicin e, [B-CAL] the concentration of bound calicheamicin E, or occupied
binding sites, and
[B-CAL]
a = [B] [CAL],
it can be shown that the amount of bound calicheamicin is described by
-b + 4 (3.3)[B-CAL] = [CAL]T 
- 2 (3.3)
1 [CAL]T
where b = [CAL]T - [B]T + ka c= - - ka and the subscript T refers to total --
known -- concentrations. If we make the extremely simplistic assumption that drug
binding and the change in mean circle size are directly proportional, then
m = mul 100 l) (percentage of occupied binding sites) (3.4)m~ ~~ ul+ ..
where m is the mean circle size at a specific drug concentration and mil and mul are
the lower and upper limits on the mean circle size respectively. Since the
percentage of occupied binding sites is [B-CAL]/[B]T, then
[CAL]T 1 -b + b-4a
m = mul+d [B]T - [B]T 2 (3.5)
where d is (mll - mul)/100.
The above equation was fit to the data for the in-phase monomer optimizing
the values of Ka and d to minimize the least square error using a Levenberg-
Marquardt algorithm (KaleidaGraph). The results are shown in Figure 3.16.
Interestingly, the estimate of the binding constant Ka is reasonable. The value of 4 x
105 M-1 is approximately half of that estimated for calicheamicin and approximately
7 times the binding constant for calicheamicin e estimated by Chatterjee et al. [67]
and Krishnamurthy et al. [42].
In the above derivation, many assumptions were used to simplify an
extremely complicated behavior. It is unlikely that calicheamicin binding can be
described by the model proposed and even less probable that the change in mean
circle size is directly proportional to drug binding. A more rigorous approach would
include 'nearest neighbor effects in the binding equation and develop a non-linear
model for the variation of mean circle size with calicheamicin binding. Regardless,
the results are reasonable enough to suggest that it may be possible to accurately
determine binding constants from a DNA cyclization experiment.
Using the mean of the circle size distribution as a measure of the ring closure
probability. While useful as a qualitative indicator of DNA behavior, is it possible
that the distribution of circles in a ligation experiment provides a meaningful
measure of the cyclization properties of the DNA substrate. In other words, how
does the mean circle size relate to the actual kinetics of cyclization?
In the T4 ligase catalyzed cyclization experiments performed here, individual
monomers polymerize until they reach a size where cyclization is favored over
further polymerization. It is a complicated series of reactions involving molecules
of many sizes cyclizing at different rates. An examination of the reaction products at
a single point in time does not allow a determination of how fast an individual
DNA polymer is converted to a circular or higher-order polymer product.
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As a result, a true measure of the ring closure probability -- the ratio of the two
equilibrium constants for the cyclization and dimerization reactions -- cannot be
determined for a specific DNA molecule in the reaction. These experiments do,
however, suggest that the mean of the circle distribution may be a relative measure
of the average ring closure probabilities for the population of DNA molecules in the
cyclization reaction.
To understand how the circle distribution from the polymerization assay
reflects the kinetics of the competing cyclization and bimolecular association
reactions, the experiments were repeated at multiple ligase and DNA
concentrations. This is premised upon the fact that the reactions of unimolecular
cyclization and bimolecular association are linearly dependent upon ligase
concentration and are first and second order with respect to DNA concentration,
respectively [52, 74]. (See Chapter IV for a detailed derivation of these expressions.)
Over a range of ligase concentrations, from 40 to 40,000 U/ml in a 50 tl reaction with
120 ng DNA, there was little shift in the distribution of circles (data not shown). The
DNA concentration (0.18 gM monomer oligonucleotide) was well below the
estimated Km for T4 ligase of -0.6 pgM [75, 76]. The observation that the distribution
of circle sizes is insensitive to changes in ligase concentration suggests that the mean
circle size may be a measure of the ratio of the two individual rates at which the two
reaction products form.
This conclusion is further supported by the dependence of the mean on DNA
concentration. Since cyclization and bimolecular association are first and second
order reactions, respectively, the ratio of the rate constants, and thus the distribution
of circle sizes, should not be constant as the DNA concentration varies. To test this
hypothesis, the effect of DNA concentration on the mean circle size was determined.
The results are shown in Figure 3.17. The mean circle size increases with increasing
DNA concentration until a plateau is reached at -500 nM bp (-24 nM monomer
oligonucleotide). This observation is consistent with the hypothesis that the mean
reflects relative rates of product formation and not just cyclization alone. At low
DNA concentrations, the probability that the ends of different DNA molecules will
find each other is small when compared to the probability of intramolecular circle
formation. As a result, smaller circles form more easily and the mean circle size is
small. As the DNA concentration increases, the rate of linear polymer formation
competes with the intramolecular cyclization thereby increasing the proportion of
larger circles and thus increasing the mean circle size. Ultimately, the process is
limited when, at high DNA concentrations, the longer polymers cyclize much faster
than they polymerize. This has the effect of placing an upper bound on the
observed mean circle size. As seen in Figure 3.17, our data reflect these
characteristics and suggest that the mean circle size is a measure of the relative rates
of product formation of both the cyclization and bimolecular association reactions.
Further analysis may allow us to derive a direct relationship between changes in the
mean circle size and the probability of ring closure, possibly allowing an explicit
quantification of DNA bending.
Summary
We have found that calicheamicin E bends DNA when it binds and that it is
the oligosaccharide tail that appears to be a major contributor to these structural
changes. These results suggest that calicheamicin likely prefers to bind sequences
that can be easily bent or "trapped" (i.e., flexible) into a conformation that
maximizes its other interactions with DNA. This further implies that DNA
sequences already bent into a conformation preferred by the drug would also be
desirable substrates for calicheamicin binding. This situation is analogous to that-of
several antibiotics that modify DNA covalently (e.g., [44, 77, 78]).
A structure and dynamics based paradigm for calicheamicin target
recognition enables us to explain why, as discussed earlier, calicheamicin-
induced DNA damage is influenced by the sequence context and overall topology
of the binding site. Since calicheamicin binding depends on DNA flexibility,
adjacent bases can affect drug binding by changing the dynamic behavior of the
target sequence; an effect that may extend for several base pairs [79, 80]. In
contrast, changes in DNA topology must precisely match the desired drug-bound
conformation to facilitate drug binding. For example, in the nucleosome studies
described in Chapter I [24, 43, 81], DNA bending reduced or had no effect on
calicheamicin-induced DNA damage except at one site. This is consistent with
the suggestion that calicheamicin does not target curved or bent DNA
indiscriminately but instead, binds only those sequences bent into a specific
conformation.
Although important to the recognition process, DNA structure and
dynamics are not the solitary determinants of calicheamicin binding. In fact, it is
clear that calicheamicin target selection is a complex process involving several
interactions that are optimized by the conformational flexibility of specific DNA
sequences. In cases where the DNA is bent or "trapped," much of the energetic
cost is taken from external forces that either bend or move the DNA. However,
for those DNA targets considered "straight," a balance must be achieved between
the DNA's intrinsic resistance to movement and those forces -- electrostatic and
hydrophobic -- that bind calicheamicin to DNA. In addition, since the binding
characteristics of individual sequences are heterogeneous, we should expect not
one, but several, optimal binding scenarios; each unique to a particular sequence.
As a result, the degree of flexibility required or the amount of bending induced,
need not be uniform across all calicheamicin binding sites. A comprehensive
model for calicheamicin binding and the other factors that contribute to the
target identification process is presented in Chapter VI.
The results with calicheamicin also demonstrate the utility of the T4
ligase/BAL-31 approach. The circle distributions clearly reflect the kinetics of the
competing reactions, though more studies are needed to rigorously define the
quantitative relationships. With the appropriate DNA constructs, this technique
should be useful for rapidly screening many small molecules and proteins for their
ability to bend DNA.
Table 3.1 Reaction conditions for the DNA polymerization experiment.
a Calculations were based on two binding sites
binding constant Ka = 1 x 106 M-1.
per monomer and an assumed
[CAL-e] [DNA] [binding sites] % binding site moles drug
_ tM mM bp jgM occupieda per bpa
400 2-4 352 99-8 108-3
40 2-4 352 97-5 10-8
20 2-4 352 95-2 5-42
10 2-4 352 90-6 2-71
5 2.4 352 82-5 1-354
2.5 2-4 352 69-3 0-677
1-88 2-4 352 62-3 0-508
1-25 2-4 352 51-7 0-339
0-63 2-4 352 33-6 0-169
0-31 2-4 352 19-6 0-085
0-08 2-4 352 5-5 0-022
0-02 2-4 352 1-4 0.005
0 2-4 352 0 0
Table 3.2 Calculating the circle distribution.
Total normalized radioactivity = 2109
Mean circle size =
a Radioactivity in each band divided by the circle size (in monomers) present in
the band.
b Normalized radioactivity in each band expressed as a percentage of total
normalized radioactivity.
Circle Size Radioactivity in Normalized Percentage of
(monomers) band (cpm) radioactivitya each circleb
14 338 24 1-2
13 783 60 2-9
12 1492 124 5.9
11 2369 215 10-2
10 3074 307 14-6
9 3504 389 18-5
8 3224 403 19.1
7 2563 366 17-4
6 1128 188 8-9
5 153 30 1.5
8.83
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Figure 3.1. Calicheamicin '71 was reduced to calicheamicin E using methyl thioglycolate as discussed in the text. The
reaction products were seperated by HPLC using a linear gradient from 42.5 mM triethylamine (pH 6-0) in 15%
acetonitrile to 20 mM triethylamine (pH 6-0) in 60% acetonitrile in 25 minutes.
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Figure 3.2. Calicheamicin 8 induced DNA damage in the out-of-phase construct.
Cloned plasmids containing 15 repeats of the out-of-phase DNA construct were
digested with Xba I and 5'-[32p] end-labeled. Following digestion with EcoR I, the
labeled fragment was purified by elution from an 8% polyacrylamide gel. Damage
reactions consisted of labeled DNA (-30,000 cpm), 30 gg/ml of calf thymus DNA, 10
mM glutathione, 10 mM HEPES, 1 mM EDTA (pH 7). The reaction was initiated by
adding calicheamicin 0 and then glutathione at the appropriate concentrations.
After incubation at 370C, the DNA was ethanol precipitated and resolved on a 6%
sequencing gel. Bands were quantitated by phosphorimager analysis.
second direction
(chloroquine at 50 gtg/ml)
first direction
(no chloroquine)
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Figure 3.3. Resolving circular from linear DNA by two-dimensional gel
electrophoresis. Products from a cyclization reaction are resolved first on an 8%
non-denaturing gel and second on an 8% nondenaturing gel containing 50 gg/ml
chloroquine. Bands along the diagonal are relaxed circles, supercoiled circles and
linear DNA. Bands in the vertical lane on left are linear DNA markers run in the
second dimension only.
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Figure 3.4. Effect of BAL-31 on the products of a T4 ligase reaction with the in-phase
calicheamicin binding site construct. Following a ligation reaction of the
oligonucleotide construct with T4 DNA ligase, linear DNA polymers were removed
by digestion with BAL-31 as described in the text. The DNA was then resolved on a
6% non-denaturing polyacrylamide gel and subjected to phosphorimager analysis.
The intensity of the radioactivity in the first lane is due to the high DNA
concentration used in this experiment (3 gg/ml) to illustrate the effect of BAL-31
digestion.
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Figure 3.5. Effect of BAL-31 concentration on the distribution of DNA circles
resulting from ligation of the in-phase calicheamicin binding site construct. DNA
circle bands in the gel in Figure 3.4 were quantified by phosphorimager analysis and
their intensities normalized to total radioactivity of all the circles measured. BAL-31
concentrations: 4 U/ml (open circles) and 40 U/ml (closed circles); 1 hr incubation
for both concentrations.
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Figure 3.6. Effect of BAL-31 concentration on the distribution of DNA circles
resulting from ligation of the A-tract construct. Following ligation of the A-tract
construct with T4 DNA ligase, the products were subjected to digestion with BAL-31
as follows: 5 U/ml for 30 min (closed circles), 10 U/ml for 30 min (open circles), and
10 U/ml for 60 min (triangles). Digestion products were then resolved on an 8%
non-denaturing polyacrylamide gel and the DNA circles quantified as described in
Materials and Methods.
[CAL], jM
40 20 10 5
.
14 5
11-
9 -Dow- t
8r
2.5 1.9 1.3 0.6 0.3 .078 .02 0
Io
.i : ,;
* 1Wc~~ UP
U, a ~ us '
W -
w o1W1
7 q 1W
5-
Figure 3.7. The effect of calicheamicin E on the formation of DNA circles from the
in-phase construct. Monomer DNA, ± calicheamicin E, was treated with DNA ligase
and digested with BAL-31 to remove linear polymers. Reaction products were
resolved on a 10% polyacrylamide gel.
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Figure 3.8. Identification of circle size by denaturing gel electrophoresis. Putativeradiolabeled DNA circles were excised and eluted from an 8% nondenaturingpolyacrylamide gel. DNA was heat denatured and resolved on an 8% denaturing gelwith 6 M urea. Duplex DNA circles denature into three products: catenanes (fromintact circles), single stranded circles and linear single stranded DNA (from nickedcircles). Lane L contains denatured linear polymers adjacent to a molecular weightmarker (lane MW) for size identification. The complementary strands of linearmolecules migrate separately due to sequence differences.
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Figure 3.9. Distribution of DNA circles as a function of calicheamicin E
concentration for the in-phase construct. Individual circle populations were
quantitated by phosphorimager analysis and normalized by size. The amount
represents the fraction of total counts measured over the 10 circle sizes.
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Figure 3.10. Plot of the mean circle size as a function of calicheamicin e
concentration for the in-phase DNA construct. Two separate trials are shown.
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Figure 3.11. The effect of calicheamicin E on the formation of DNA circles from the
out-of-phase construct. Monomer DNA, ± calicheamicin E, was treated with DNA
ligase and digested with BAL-31 to remove linear polymers. Reaction products were
resolved on a 10% polyacrylamide gel.
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Figure 3.12. Distribution of DNA circles as a function of calicheamicin E
concentration for the out-of-phase construct. Individual circle populations were
quantified by phosphorimager analysis and normalized by size. (Not all
experiments are shown, the results at some drug concentrations have been left out
for clarity.)
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Figure 3.13. Plot of the mean circle size as a function of calicheamicin E
concentration for the in-phase construct.
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Figure 3.14. Mean circle size as a function of calicheamicin F concentration for in-
and out-of-phase DNA constructs.
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Figure 3.15. Mean circle size versus oligosacchride concentration. 120 ng of 5'-[32p]-
ATP end-labeled monomer (either the in-phase or out-of-phase construct) was
polymerized in a 50 pl reaction containing standard T4 DNA ligase reaction buffer,
the appropriate amount of oligosaccharide and 400 units of T4 DNA ligase. The
reaction was carried out overnight at 16'C. The reaction products were then
digested with BAL-31 and the circular products resolved by gel electrophoresis and
quantitated by phosphoimager analysis.
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Figure 3.16. Estimating the binding constant of caleachimicin e. Binding constant
was determined by optimizing the fit of
S[CAL]T 1 -b + 4a
[B]T [B]T 2
to the distribution of mean circle sizes for the in-phase DNA construct. (See text,
equation 3.5, for definition of terms.)
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Figure 3.17. Effect of DNA concentration on the distribution of circle sizes resulting
from the ligation of the calicheamicin binding site construct. Various
concentrations of the calicheamicin binding site construct were subjected to reaction
with T4 DNA ligase (8000 U/ml). The ligation products were then digested with
Bal-31 (40 U/ml for 1 hr at 30 0 C) and the remaining circles were resolved on a 6%
non-denaturing polyacrylamide gel. The mean circle size at each DNA
concentration was determined as described in the text.
CHAPTER IV
Calicheamicin binding and DNA Cyclization Kinetics
The experiments described in Chapter III show that calicheamicin bends DNA
upon binding. However, the mean of the circle size distributions is a relatively
insensitive and -- at best -- a qualitative measure of cyclization probability. As
reviewed in Chapter I, a more rigorous approach towards determining the structural
changes that affect the probability of DNA circle formation is to examine the
cyclization and dimerization behavior of a single polymer under conditions that
allow all of the reaction products to be identified. An analysis of how these products
vary over time allows an explicit evaluation of the reaction kinetics and a direct
determination of the probability of polymer cyclization. Understanding how this
probability changes as calicheamicin binds may then allow us to better understand --
and possibly quantify -- the structural changes in DNA resulting from calicheamicin
binding.
The design of an experiment to measure the kinetic properties of a cyclizing
molecule requires a careful consideration of the theoretical framework used to
analyze the data. In other words, we must ensure that the test substrates and
reaction conditions yield results that are consistent with the assumptions made in
deriving the theoretical models used to calculate the reaction kinetics. To
understand what these assumptions are and how they affect the experimental design
we must first derive theoretical expressions for the rate constants we intend to
measure.
Theoretical Background
Derived from polymer chain statistics, the ring closure probability (J factor or
Jacobson-Stockmayer factor) is defined as the ratio:
Kc
J Ka
where Kc and Ka are the equilibrium constants for cyclization and bimolecular
association, respectively [67]. Depending on the concentration of one end about the
other, J can be thought of as the molar concentration of DNA required to cause
bimolecular joining to occur at the same rate as the corresponding cyclization
reaction [53, 56, 82]. Since the formation of small DNA circles requires large
fluctuations in the shape of the molecule, the cyclization equilibria are quite
sensitive to the conformation and mechanical rigidity of the chain. As a result,
measurements of J are ideally suited to characterizing the structural and dynamic
characteristics of DNA.
Shore, Langowski and Baldwin [52, 74, 83] built upon the work of Wang and
Davidson [82, 84] and were the first to measure the J factor using T4 DNA ligase.
This advance allowed smaller restriction fragments with shorter complementary
ends to be used since the ends did not normally associate with each other strongly
enough to be detectable by other means. Since then, much work has been done
within the Crothers and Hagerman groups to use this technique to explore the static
and dynamic behavior of DNA [50, 53, 57, 59, 60, 71, 85-87]. The theoretical
background presented here explains or derives from their seminal works.
The kinetics of cyclizing molecules. A schematic representation of the cyclization of
a double stranded piece of DNA with complementary overhanging ends, is shown
below:
k12 k 3 k34
--- +
k12 k30
DNA Ligatable Enzyme-Substrate Closed DNA Enzyme
Substrate [L] Substrate [S] Complex [ES] [P] [E]
Symbolically,
k 12
[L] [S] + [E] [ES] -~- [P] + [E]
(4.1)
This assumes that the second strand of DNA is rapidly ligated after the first and that
covalent closure can be considered a single reaction.
To derive a rate constant for the formation of cyclized product [P], we assume
that enzymatic modification by the ligase, k34, is the rate limiting step. In other
words, the formation of the ligatable substrate and the association of the ligase
enzyme occur much faster than the actual enzymatic modification to the DNA.
(The validity of this assumption has been demonstrated by the predictive power of
the resulting equations.) Since k34 is rate limiting, steady state conditions are
reached upstream such that
d[S]
dt
d [ES]
and tdt
Applying the second of these conditions to the reaction outlined in equation 4.1
yields
k 23[ES] = (k32 + k34)[S][E].
S(32 + k34)
(4.2)
Similarly, the first steady state condition results in
0 = [L]k 12 - [S]k 21 - [S][E]k 23 + [ES]k 32-
Substituting the latter into the former and solving for [L] gives,
(k21 + [E] f34 k23)[L] = [S] t_
k3 4
where f34 = (k32 + k34)
To make use of this result, we must first relate the kinetics of [L] to a measurable rate
constant, and then express it in terms of known quantities other than [E] and [S],
(4.3)
which are difficult to determine experimentally. The former is addressed now and
the latter in following sections.
The empirically observable quantities in a cyclization experiment are the
product, the cyclized DNA [P], and the uncyclized substrate [D] where [D] = [L] + [S].
To relate these quantities to the kinetics of [L], we note that the rate of disappearance
of [D] with respect to time -- d[D]/dt -- has been shown to be directly proportional to
the amount of uncyclized substrate [52]. In other words, the disappearance of [D] is
first order such that
d[D]
dt = - k [D]
d[D]/dt
or k= 
- [D]
where kl is the first order rate constant for the disappearance of uncyclized substrate
[D]. From the reaction outline in equation 4.1, the generation of cyclized product [P]
is also first order and can be written as
d[P]
dt - [ES] k34. (4.5)
However, since steady state condition exists in the intervening steps (i.e., d[S]/dt =
d[ES]/dt = 0),
d[L] d[P]
dt - dt
We can now relate k, to [L] by first noting that [D] = [L] + [S] can be differentiated
with respect to time to get
d[D] d[L]
dt dt
d[S]
+ dt
d[D] d[L]
or dt = dt
since d[S]/dt = 0 from the assumption of steady state. Substituting equation 4.7 into
equation 4.4 gives
d[L]
k1 [D] = - dt '
which can, by using equations 4.5 and 4.6, be written as
k1 [D] = [ES] k34.
(4.4)
(4.6)
(4.7)
Substituting in the earlier expression for [ES], gives
k 23kl [D] = (k32 + k34)[S][E] k34 = [S][E] f34 k23,
which, since [D] = [L] + [S], can be written as
[S][E] f34 k23
S= [L] + [S]
Using equation 4.3 to replace [L] in the above, gives the following expression for kl;
[E] f34 k23 k12 (4.8)k, =
where k1 is the observed rate of disappearance of uncyclized DNA and [E] is the
concentration of free ligase [52]. Equation 4.8 is premised upon the assumption that
the ligation event is rate limiting and that steady state conditions exist prior to
ligation.
The kinetics of dimerizing molecules. The process of bimolecular association of
identical half molecules with complementary overhanging ends is shown
schematically below.
a ba b
b ab aI
k 34  [P']
[E]
[E]
Half
Molecules [H]
Ligatable
Substrate [Sa]
Enzyme-Substrate
Complex [ES]
Symbolically, the reaction is,
[ES] - -- [P'] + [E]
a b 12
Iny in
rIn| ni
2 [H]
(4.9)
k12 k23
[Sa] + [E]
Analogous to the cyclization reaction, it is assumed that enzymatic ligation is the
rate limiting step and that steady state conditions exist upstream. Applying these
assumptions, as before, gives the following two expressions;
k23[ES] = (k32 + k3 4) [S][E] (4.10)
and
0 = k1 2 [H] 2 - [S] k12 - [S] [E] k23 + [ES] k32, (4.11)
where the term (1/2)k12 [H]2 arises from the fact that 2 molecules of [H] self-react to
form only one molecule of [S]. Substituting 4.10 into 4.11 and solving for [S] yields,
Ik 12 [H]2
[Sa] = k21 + [E] k23 34 (4.12)
As before, to make use of this result, we must relate the kinetics of [S] to an
experimentally measurable rate constant. It has been observed, that in a reaction in
which a linearized half molecule forms a dimer product [P'], the disappearance of
[D'], where [D'] is the concentration of undimerized substrate ([H] + 2[S]), with
respect to time is second order. Therefore, the rate constant for bimolecular
association, k2 is defined by
d[D']
d[D'] 2 dt
dt -k 2 [D'] or k2 = - [D'] 2  (4.13)
From the reaction outlined in 4.11, the generation of dimerized product [P'] is first
order, so
d[P'] [ES] d [H] dP'] (4.14) and (4.15)dt -[ES]k 34  and 2 dt -- dt
(Equation 4.15 results from the assumption of steady state conditions and the fact
that 2 molecules of [H] are used to produce one dimer [P'].) To relate the
experimentally observed k2 to the kinetic relationship derived above, we note that
the equation [D'] = [H] +2[S] can be differentiated with respect to time to get
d[D'] d[H] d[S]
dt dt dt
(under steady state conditions).
d[D'] d[H]
or dt = dt
Substituting this result into 4.13 results in
d[H]
dt
k2  [D']2 '
which can be further manipulated via equations 4.14, 4.15 and 4.10 to get
2 [ES] k34
k2 [D']2
2 k 3 2 + k 3 4 [Sa] 
[E] k34
[D']2
which simplifies to
2 f34 k23 [Sa] [E]
k2 =
Substituting in equation 4.12 for [Sa] gives
k2 1 rf34 k23 k12 [E] [H]
2]
2 - [D']2 I k21 + [E] k23 f34 j (4.17)
where k2 is the observed rate of disappearance of undimerized DNA, [D'] is the
amount of unligated half molecules, [E] is the concentration of free ligase and [H] the
concentration of unligated half-molecules. As in the case of cyclizing molecules, it
was assumed that the ligation event was rate limiting and that steady state
conditions existed prior to ligation.
Monomer kinetics assuming pre-equilibrium and rapid ligase disassociation.
Equation 4.8 for cyclizing molecules and equation 4.17 for dimerizing molecules can
be further simplified by assuming that the interconversion between the unligatable
(4.16)
substrates, [L] and [H], to the ligatable substrates, [S] and [Sa], occurs extremely fast
and that, as a result, these populations exist in a pre-equilibrium state [52].
Therefore, we can define the equilibrium constants Kc and Ka such that
K 12
Kc 
-k21
Ka k12
Ka-k21
for cyclizing molecules, and
for dimerizing molecules.
Equation 4.8 can, after dividing by k21/k 21, be rewritten as
Kc f34 [E] k23
kI = k23
Kc + 1 + [E] f34 k21
Similarly, equation 4.17 can be written in terms of its equilibrium constant as
1 Ka f34 k23 [E] [H] 2
k -2 [D']2 l+[E]k23
If we further assume that the ligase disassociates from the ligatable substrate
much faster than it binds (i.e., k21 >> k23), then the above equations can be reduced
to
kl = (i
Kc
Kc +1 f34 [E] k 23
and
Ka f34 k23 [E] [H]2
k 2 = - [D] 2[D']2
(4:18)
(4.19)
These equations can be further simplified by defining the term fs and fs' as the
[S] 2[Sa]fractions of ligatable substrate for cyclization, fs - p] , and dimerization, fs = [D']
Noting that
[S] fs
[L]M = 1 - fs
allows equation 4.18 to be rewritten as
k, = Kc f34 [E] k23 (1 - fs). (4.20)
Similarly, by noting that
[H] [H [H [H]
[D'] = [D] -I [H]/[D']= [D'] - 2[S] - 1 fs'
[D']
and that therefore,
[H]2[D']2 = (1- fs') 2
equation 4.19 can be rewritten as
k2 = Ka f34 k23 [E] (1 - fs') 2.  (4.21)
In deriving equations 4.20 and 4.21, two more assumptions were made: 1) the
interconversion between the unligatable substrate to the ligatable DNA occurs
extremely fast and 2) the rate of ligase disassociation is much greater that the rate of
ligase association with the ligatable substrate.
Monomer kinetics in terms of initial ligase concentration. To avoid the need to
experimentally determine the concentration of free ligase [E], it is useful to derive
expressions for kl and k2 in terms of the total enzyme concentration [EO] where [Eo] =
[E] + [ES]. Substituting in the kinetic relationship for [ES], which is the same in
either the cyclization or dimerization reactions (equations and 4.2 and 4.10), and
solving for [E] results in
1 = k34 [Eo] k32 + k34[E] - f34 k2 3 Km + [S] where Km = k23
Replacing [E] in equations 4.20 and 4.21 with the above expression gives
84
Kc k34 [Eo] (1 - fs)
kl = K + S] (4.22)
and
Ka k34 [Eo] (1 - fs')2
k2 Km + [Sa] (4.23)
where, to summarize:
* kl is the rate of disappearance of the uncyclized substrate [D], a first order
rate constant;
* Kc is the equilibrium constant between the linear [L], and ligatable [S],
substrates;
* k2 is the rate of disappearance of the monomer substrate [D'], a second
order rate constant;
* Ka is the equilibrium constant between the monomer [H], and the ligatable
dimer [Sa];
* [EO] is the total ligase concentration;
* Km is the rate constant for the DNA ligase; and
* fs and fs' are the fractions of ligatable substrate for the cyclization and
dimerization reactions respectively.
In deriving these equations it was assumed that: 1) the ligation event is the
rate limiting step; 2) steady state conditions exist prior to the ligation event; 3) the
interconversion of non-ligatable and ligatable substrate is fast and, as a result, a state
of pre-equilibrium exists between the two; and 4) that rate of ligase disassociation is
much greater than the rate of association with a ligatable substrate. Shore et al.
demonstrated the validity of these assumptions empirically, by matching
experimental data with the predicted results [52].
Equations 4.22 and 4.23 represent the rate constants for the conversion of a
DNA molecule into a polymer or circle respectively. An evaluation of these rates
allows a direct determination of the ring closure probability, J, as shown below.
Experimental Design
The ring closure probability, J, can be determined by solving equations 4.22
and 4.23 for the equilibrium constants Kc and Ka and taking the ratio:
k1 (Km + [S])
Kc 1 -fs
J Ka k2 (Km + [Sa])
(1- f s') 2
If: 1) the concentration of ligatable substrates [S] and [Sa] are small with respect
to Km and
2) the ratio of ligatable substrate to total unligated DNA fs and fs' are much
less than 1 (i.e., < 0.03; [52]),
then the above expression reduces to
klJ k2. (4.24)
Therefore, under certain conditions we can approximate the ring closure probability
by empirically measuring the two rate constants kl and k2. Our experimental
approach was to design a DNA test specimen that allowed us to easily alter the
amount of ligatable substrate while developing a robust strategy for measuring the
rate constants under a variety of reaction conditions.
Test specimen design. To optimize the change in the probability of cyclization in'
response to calicheamicin binding, we used test constructs that were polymers of the
in-phase binding site construct. Families of different sized polymers were generated
by cloning products from the ligation of the in-phase monomer. As a result, we
could select the molecule length that gave us structural and dynamic characteristics
necessary to remain within the theoretical constraints of our analysis.
In general, the goal was to ensure that the fraction of substrate available for
cyclization (fs) or dimerization (fs) was very small and that the total amount of
ligatable substrate ([S] or [Sa]) was an order of magnitude less than the Km for the
DNA ligase (estimated at 0.6 ptM) [75, 76]. The fs' and fs can become large if, in the
case of the former, the DNA concentration is high or, in the case of the latter, if the
molecule cylcizes easily (J = 10-6 M) [53]. The amount of ligatable substrate ([S] or
[Sa]), is directly dependent on fs, fs and the total concentration of DNA. Therefore,
the experiments relied upon choosing the correct molecule length and reaction
conditions to ensure that none of the assumptions made in the derivations were
violated.
Measurement of rate constants. In general, there are two approaches to empirically
determine the rate constants kl and k2 for a specific DNA molecule: 1) perform
independent reactions or 2) measure kj and k2 simultaneously in one reaction.
To measure the rate constants ki and k2 independently, two separate ligation
experiments are performed under conditions designed to produce only one of the
two possible reaction products, circles or dimers [56]. This can be achieved in two
ways. In the first, the DNA concentration is altered to shift the reaction towards one
product while excluding the other. In this case, measurements of kl are performed
at DNA concentrations too low for dimerization to occur at an appreciable rate,
while k2 is measured at high DNA concentrations, which increases the rate of
bimolecular association well above the rate of cyclization. A second technique
inhibits cyclization and allows k2 to be measured directly by using a DNA molecule
that is too short to cyclize. Since k2 is independent of polymer length, the rate
constant for the short DNA is equivalent to that of the larger [52]. There are several
problems with these approaches. The first technique may not be appropriate for
molecules that cyclize easily since the amount of DNA necessary to convert all the
substrate directly to dimers may make fs large and equation 4.24 invalid. The
second may not work if the assumption that kl and k2 are independent is wrong.
This may be the case when kl is large. Last, both techniques are susceptible to errors
introduced by having two separate experiments. Differences in ligase concentration
or other impurities that influence DNA structure, dynamics or ligation efficiency
could all cause experimental artifacts.
To avoid the errors associated with two independent experiments, J can be
determined from a reaction in which both circular and polymer products are formed
simultaneously. A schematic of such a scenario is shown below.
[C(t)]
circles
[M(t)]
monomers
[Di(t)] 
dimers
Higher order products
- dimer circles
- trimers
- trimer circle
- etc.
The rate constants kl and k2 are identical to those of the individual reactions in
which only one product is formed. In this case,
kI k2
[M(t)] - [C(t)] and 2 [M(t)] 0 [Di(t)] (4.25) and (4.26)
Note, that if dimerization occurs rapidly, then higher order polymers and polymer
circles may be generated. This becomes a problem when the proportion of
multimers -- which can still act as substrates for dimerization -- is large enough to
compete with the existing monomers in further polymerization reactions.
Fortunately, the larger polymers often cyclize quickly and are taken out of the pool
of reacting substrates.
The kinetics of these competing reactions (neglecting the formation of higher
order products) are described by three partial differential equations [53]:
The rate of circle formation;
The rate of dimer formation;
And, the loss of monomer substrate:
d[C(t)]
dt - kl [M(t)].
d[Di(t)] 2
dt = 2 k2 [M(t)] .
d [M(t)]
dt - - k, [M(t)] - 4 k2 [M(t)]
2
.
The factor of 2 in equation 4.28 results from the two ways in which polymers with
different, but complementary, ends can come together to form a dimer. The
coefficient of 4 in equation 4.29 occurs since the rate at which the dimerized product
is generated is 1/2 the rate at which monomer, going to form dimer, is lost (two
moles of monomer go to form one mole of dimer). Solving the above system of
(4.27)
(4:28)
(4.29)
differential equations with the initial conditions that [C(0)] = [Di(0)] = 0 and [M(0)] =
Mo, results in
Mo e
[M(t)] = k2 , (4.30)
1 + 4 Mo (1 - e -k t)
[C(t)] =- 4 -kit + In[M)]} , and (4.31)
1[Di(t)] = (Mo - [C(t)] - [M(t)]) . (4.32)
The above equations can be used to estimate the rate constants kI and k2 by
optimizing their fit to the measured data. (See Materials and Methods.) The ring
closure probability, J, can then be calculated by taking the ratio of the two reaction
rates if the conditions of equation 4.24 are met.
Another method, proposed by Taylor and Hagerman, evaluates J directly by
extrapolating the measured data backwards to estimate the reaction products as soon
as the reaction starts [57]. If we take the limit of equations 4.26 and 4.26 over a small
interval of time,
limt- 0 [C(t)] = k1 [Mo] t
limt_ 0 [Di(t)] = 2 k2 [Mo 2 t
then, from equation 4.24, we can then write
([C(t)] ,
J = 2 [Mo] limt- 0 [Di(t)]) (4.33)
Equation 4.33 can be used to solve for J directly by measuring [C(t)] and [Di(t)],
extrapolating back to t = 0 to find the limit, and dividing.
Although both the above techniques were tried, the Crother's method
allowed an explicit determination of the rate constants, that proved more useful.
Materials and Methods
Reagents and DNA substrates. Calicheamicins 711 and s were provided by Dr. George
Ellestad (Wyeth Ayerst Research) or synthesized as described in Chapter II;
calicheamicin 8 and the aryltetrasaccharide were provided by Prof. K.C. Nicolaou
(Scripps Research Institute). All enzymes were obtained from New England Biolabs.
Deoxyoligonucleotides were prepared as described in Chapter II.
Preparation of large quantities of a specific polymer construct. Clones containing
specific polymers were constructed and identified as described in Chapter II. Large
quantities of the polymer substrate were grown and purified as follows. The
appropriate vector was electroporated into the GM1206 E. coli host and cultured in
LB (10 grams tryptone, 10 grams yeast extract, 5 grams NaC12 and 2 grams MgC12 in 1
L H20 adjusted to pH 7-2 with NaOH) and chloramphenicol as described elsewhere
[64]. Plasmid DNA was isolated using Qiagen Giga-Preps (Qiagen) and purified, if
necessary, on a CsCl gradient to remove genomic contamination. Polymer
constructs were recovered by digesting the plasmids with Sap I (1 unit/Gig under
standard reaction conditions) followed by gel purification.
Preparation of radiolabeled DNA. DNA polymers used in the cyclization
experiments were radiolabeled as follows: 1 pM of 5' ends were dephosphorylated
for 40 minutes at 37°C with alkaline phosphatase under standard conditions
(Boehringer) in a 50 gl reaction containing 0-02 units/pmole of calf intestinal
alkaline phosphatase (diluted in 25 mM Tris-HC1, 1 mM MgC12, 0-1 mM ZnC12, 50%
glycerol, pH 7.4 prior to use). After heating 10 minutes at 65°C to kill the enzyme,
the DNA was extracted once with phenol, once with phenol/chloroform and
desalted using a G-50 sephadex spin column (Boehringer). Labeling of the 5' end
with [32p] was performed in an 80 tl reaction containing 150 gCi of 7-[32P]-ATP
(-6,000 mCi/mmole) and 20 units of T4 polynucleotide kinase in standard reaction
buffer (NEB) for 1 hr at 37°C. The DNA was then extracted once with phenol, once
with phenol/chloroform and the unincorporated ATP removed on a G-50 sephadex
spin column. The DNA was immediately diluted to a total volume of 0.1 or 1 ml to
reduce radiolytic degradation. The degree of phosphorylation in the radiolabeled
substrate was determined by performing overnight ligation reactions at very low
DNA concentrations (< 1 fM) under standard conditions and separating the products
on a 4% polyacrylamide gel containing 60 gM chloroquine. The gel was dried and
subjected to phosphorimager analysis (Molecular Dynamics). Labeling the DNA in
the above manner resulted in greater than 95% phosphorylation of the 5' ends.
DNA cyclization reactions. The circle closure experiments were performed as
follows: A mixture of 5'-[ 32p] end-labeled polymer and unlabeled DNA, at a ratio of
less than 1:20, was ligated at 160C in a 40 ftl reaction mixture containing 65 nM DNA,
50 mM Tris-HCl (pH 7-6), 3-5 mM MgC12, 5 mM KC12, 1 mM dithiothreitol, 1 mM
ATP, 40 tg/ml bovine serum albumin, 0.1% Nonidet P-40, and 2.5% v/v MeOH
containing calicheamicin e ranging in concentration form 0 to 100 gM. After
removing a 4 l aliquot and quenching as described below, the ligation reaction was
initiated by adding 1 tl of T4 DNA Ligase (0-04 to 40 units/gtl); diluted in 50 mM
KCl2, 10 mM TrisHC1, 0.1 mM EDTA, 1 mM DTT, 200 jtg/ml BSA and 0.1% Nonidet
P-40 just prior to use. Ligase stocks were stored in an identical buffer without NP-40
but with 50% glycerol. At specific time intervals, 4 tl aliquots were removed and
quenched in 4 gl of preheated (65C) stop and loading buffer (100 mM EDTA, 5%
v/v glycerol and 0-04% w/v bromophenol blue). Samples were then incubated at
65°C for > 10 minutes, cooled to room temperature and loaded directly onto either a
4% composite agarose gel (2% NuSeive GTG and 2% high-melting agarose) or a 4%
non-denaturing polyacrylamide gel. In both cases, the gels were dried and subject to
phosphorimager analysis.
Methods of Analysis
After performing a cyclization experiment, the reaction products were
resolved by polyacrylamide gel electrophoresis and quantified by phosphorimager
analysis. The techniques used to evaluate the rate constants were unique to the
specific experimental outcome: circles only, polymers only or both circles and
polymers.
Case I: Circles only. In ligation experiments where the substrate was converted to
circles only, k1 was determined by measuring the slope of line produced by plotting
the natural log of [M(t)]/[Mo] versus time.
From differential equation 4.27, the loss of cyclizable substrate (equation 4.4) is
d[M(t)]
dt = - k1 [M(t)],
after separating variables and integrating,
ln[M(t)] - In[Mo] - - k1 t + C1
where [Mo] is [M(t)] at t = 0 and C1 is an integration constant. Since at time t = 0,
[M(t)] equals [Mo], C1 = 0. The above equation then becomes
[Mo]
[M(t)] = ekt or In [Mo) +kit =0.
Therefore, kl can be determined by measuring the slope of line produced by plotting
the In of [M(t)]/[Mo] versus time.
The above analysis assumed that all the substrate could cyclize. In practice, it
has been observed that between 5 to 20% of the DNA is unable to ligate [87]. To
correct for this, the amount of non-cyclized substrate, measured at a given time t, is
[Mm(t)] = [M(t)] + fd [Mmo]
where [Mm o] is the total amount of measurable substrate ([Mm(t)] at t = 0) and fd is
the fraction of total substrate that is not ligatable. Similarly,
[Mmo] = [Mol + fd [Mmo].
Substituting these last two expressions into equation 4.34 gives the following
equation for the measured amount of uncyclized substrate as a function of time and
the rate constant kl
[Mm(t)] = [Mmo] [e-kit( - fd) +fd]. (4.35)
In cases where fd was large, kl was obtained by optimizing the fit equation 4.35 to the
measured data [71]. To determine fd, the ligation reaction was allowed to continue
until the amount of non-cyclized substrate remained nearly constant. The ratio of
(4.34)
the non-cyclized substrate to total DNA was fd. All curve fitting was performed on
KaleidaGraph (Abelbeck Software).
Case II: Dimers (polymerization) only. In a ligation experiment in which the DNA
polymerizes without forming circles, the differential equation describing the
disappearance of undimerized substrate (equation 3.18) is
d[M(t)] 2
dt = - k2 [M(t)]
Again, separate variables and integrate to get
1 1
[M(t)] + [Mo] = -k2 t + C1
where [Mo] is [M(t)] at t = 0 and C1 is an integration constant. Since at t = 0, [M(t)] =
[Mo], Ci = 0. Upon rearranging, the above equation becomes
[Mo]
[M(t)] = k2 t[M ] + 1'
S[M(tl1
or [M(t)] - k2 t = 0. (4.36)
An estimate of k2 can be made from the from the slope of the line fit to the data
plotted as
1 [M(t)]
[Mo(t)]
[M(t)] versus time.
For completeness, we can again correct for the proportion of substrate unable
to dimerize by using
[Mm(t)] = [Mmo 1+ (1 - f'd)k 2t + f'd
where [Mmo] is the concentration of initial substrate and f'd is the percentage of
substrate unable to dimerize. In practice, however, it is unlikely that both ends of an
individual polymer will be unable to ligate. Therefore, f'd is much smaller than fd
and probably much less than 1. In this case, the above equation simplifies to
equation 4.36.
Unlike the cyclization reaction, the bimolecular association reaction involves
two molecules that can react in two ways with each other to form a dimer. As a
result, the rate of dimerization is two times faster than that of a molecule with one
reactive end. Therefore, once the reaction rate is computed, the result is divided by
2 to get the true rate of bimolecular association.
Case III: Both circles and dimers. When both circular and dimer products were
formed, the individual rate constants were determined by optimizing the fit of
equations 4.27 through 4.29 to the experimental data. To begin the optimization, the
rate constants were estimated using the methods described assuming that only one
product was formed. These were then refined as follows:
* New estimates of kl and k2 were made by fitting the amount of unreacted
product to the equation for [M(t)] (equation 4.29).
* A new estimate of ki was made by holding k2 fixed and optimizing the fit
of [C(t)] (equation 4.27) to the data.
* The estimate of k2 was then refined by fixing ki and optimizing the fit of
[Di(t)] (equation 4.28) to the data.
The last two steps were repeated until the individual rate constants changed by less
than two percent upon further iteration. All curve fitting and optimization was
performed using a Levenberg-Marquardt algorithm (KaleidaGraph) on a Mac
PowerPC.
To measure J directly using equation 4.33, [C(t)] and [Di(t)] were plotted versus
time and their respective limits, as t goes to zero, found by extrapolating backwards.
Since the radioactivity in the dimers represents twice the concentration of dimers, J
was determined from
(C(t)r>
J = 4 [Mo] limt_ 0 D(t)r (4.37)
where the subscript r represents measured radioactivity in the band [57].
Results and Discussion
As discussed in Chapter III, the mean of the distribution of circles formed in a
DNA polymerization experiment is a relatively insensitive -- and at best --
qualitative measure of cyclization probability. As a result, small changes in DNA
structure are likely undetectable. A more rigorous approach is to examine the
kinetics of the competing cyclization and bimolecular association reactions directly
on a single polymer. To further examine the effects of calicheamicin binding on
DNA structure, these experiments were performed on a 273 bp DNA polymer under
a wide range of calicheamicin concentrations. The data are consistent with our
earlier observations that calicheamicin bends DNA when it binds.
The effect of calicheamicin E binding on the cyclization kinetics of a 273 bp polymer.
To enhance the sensitivity a DNA polymer to bend deformations introduced by
calicheamicin binding, a molecule containing 13 repeats (273 bp) of the in-phase
binding site construct (pAS1/13m9) was used. As described earlier, calicheamicin-
induced bending in-phase with the helical repeat of B-DNA would add
constructively to induce a large planar deformation that would bring the ends of the
molecule in closer proximity, increasing the probability of cyclization.
The DNA substrate was prepared by cloning the appropriate plasmid
(pAS1/13m9 grown in E. coli strain GM2163), isolating large quantities of the vector,
digesting the DNA with Sap I and recovering the polymer by gel electrophoresis.
The cyclization reactions were performed over a broad range of calicheamicin
concentrations as described in the Materials and Methods section using the reaction
conditions summarized in Table 4.1. Individual reaction products were resolved as
shown in Figures 4.1 through 4.7 and identified by denaturing gel electrophoresis as
discussed in Chapter III.
As expected, with increasing amounts of bound calicheamicin E the reaction
shifted from bimolecular association (intermolecular) to cyclization
(intramolecular). In other words, calicheamicin binding at phased sites within the
DNA molecule led to a greater number of circles being formed. At calicheamicin
concentrations greater than 10 ptM (approximately six moles of drug for every mole
of binding site), only circles were formed.
The quantity of DNA remaining in the wells of each gel was randomly
distributed and was not related to any single reaction product. Repeated extractions
with phenol/chloroform and chloroform/isoamyl alcohol, and precipatation with
ethanol failed to improve the situation in a consistent manner. In all cases,
however, the amount in the wells was small compared to the primary reaction
products and had a negligible impact on the analysis.
The rate constants for bimolecular association and cyclization were
determined at each drug concentration as described in the Materials and Methods
section. In those cases where both circular and bimolecular products were
measured, the individual rate constants were determined by the fitting the data to
the system of partial differential equations (equations 4.30 - 4.32). For each
experiment, initial guesses for the rate constants kl and k2 were made by assuming
that only circles or dimers formed respectively (equations 4.34 and 4.36) or by fitting
the disappearance of unreacted substrate to equation 4.30. Since the percentage of
unligatable substrate was less than 5%, the correction to equation 4.34 was
unnecessary. An example of the iteration process is shown in Table 2 and graphs of
the resulting curve fit in Figure 4.9. The ring closure probability, J, was determined
by taking the ratio of the rate constants. For the calicheamicin concentrations
shown in Figure 4.1 through 4.7, the results were:
[calicheamicin] kl k2 J = kl/k2
(M) (s-1) (M-1s -1) (Molar)
0 1-52e-4 1-87e+3 8-12e-8
0.1 2-37e-4 2-46e+3 9-65e-8
0-32 3-77e-4 2-56e+3 1.47e-7
1 4-59e-4 1-80e+3 2-55e-7
3.2 8-31e-4 727 1.14e-6
10 1-23e-3 136 9-01e-6
32 All Circles
100 All Circles
The calculation of the ring closure probability relies on the assumption that
kl Kc
k2 Ka J
As discussed previously, this is true only if fs and fs' are very small and that [S] and
[Sa] are much less than the Km of T4 DNA ligase. Under these reaction conditions
with no calicheamicin e the ring closure probability of the 13m9 polymer was
approximately 10-7 M. This value is larger than that determined by other groups for
similarly sized DNA fragments [52, 74, 83], but less than that expected for a polymer
consisting of phased A-tracts [53, 56]. This is probably due to the increased length of
our complementary ends (a 3 bp overhang rather than a 2 bp), which facilitates
hydrogen bonding and thus the forming of a greater proportion of ligatable
substrate. However, since J is near or below 10-6, the relative amount of DNA
available for ligation to a circle (i.e., fs) is likely small.
To avoid using two reactions to determine the rate constants, it was
important that the DNA concentration was high enough to allow intermolecular
reactions to occur at a detectable rate. In these experiments, k2 was -- at most --
2-60x10 3 M-1s-1. This is consistent with bimolecular association rates measured with
the 5m9 polymer in earlier experiments (data not shown). In a DNA polymer with
a two base pair complementary ends, Koo et al. [56] measured a k2 of 2-4x10 2 M-1s-1,
approximately 10-times less than ours. An estimate of Ka, by temperature jump
methods, allowed them to calculate, based on a DNA concentration of 10 nM, an fs'
less than or equal to 0-0001. Given that the concentration of DNA used here is 6.7-
times greater and the fact that fs' was very small in their case, it appears reasonable
to assume that our assumption that fs' is small is also reasonable.
Finally, given the relatively small amount of DNA in the cyclization
reactions, the concentration of ligatable substrates ([S] and [Sa]) could -- at most --
equal 65 nM which is only 10% of the Km for T4 DNA ligase. Since fs and fs' are
certainly much less than one, we can reasonably assume that [S] and [Sa] are much
smaller than Km.
Since all the conditions of the theoretical analysis appear to have been met,
the ring closure probability, J, can be reasonably approximated by the ratio of the
individual rate constants k1 and k2 .
The rate constants for bimolecular association and unimolecular cyclization
for the 273 bp polymer of the in-phase binding site construct are shown in Figure
4.10. As more calicheamicin a binds the DNA, the rate of cyclization, k1, increases.
This slow rise is consistent with bending while the slight oscillatory behavior may
be the result of a small twist component. Any twist effects would likely by small
since, as mentioned in Chapter III, the intrinsic flexibility of a molecule more than
250 bp in length effectively decouples the influence of one end's position on the
other. Interestingly, the rate of dimerization, k2, drops precipitously causing a near
exponential rise in J. This may be the result of steric hindrance as the ends of the
molecule move closer together. (This observation forms the basis of the studies
described in Chapter V where it is discussed in more detail.)
The effect of aryltetrasaccharide binding on the cyclization kinetics of a 273 bp
polymer. The above experiment was repeated for the oligosaccharide side chain of
calicheamicin. The results are plotted in Figure 4.11. The response of the in-phase
polymer parallels that seen when calicheamicin E binds DNA. This result provides
further evidence that the aryltetrasaccharide is the structural motif responsible for
calicheamicin's effect on DNA topology.
Summary
The effect of calicheamicin binding on the cyclization kinetics of a polymer
with phased calicheamicin binding sites has been measured. The experiments were
carefully designed to ensure that the individual rate constants for bimolecular
association and unimolecular cyclization could be determined and used to estimate
ring closure probability. Our results support the hypothesis that calicheamicin
bends DNA when it binds and that the oligosaccharide is the structural motif
responsible for these changes.
These data provide a unique opportunity to benchmark theoretical models of
dynamic DNA behavior. Never before have the cyclization kinetics of the same
DNA molecule been measured at different levels of planar bending. Premised on
statistical mechanics and polymer chain theory, programs using Monte Carlo
simulations of DNA dynamics have been used to fit empirical data to determine the
mechanical properties of DNA. These same methods should be capable of
estimating how much bending and twisting occurs as calicheamicin binds. The
theoretical refinements should prove invaluable to our conceptual understanding
of DNA structure and dynamics.
Table 4.1. General reaction conditions and calculated calicheamicin binding data.
a The percentage of sites occupied at a specific drug concentration was determined
using equation 3.3 and assuming a Ka of 4-3 x 105 M-1.
[pAS1/13m9] (hot) < 0-65 nM
[pAS1/13m9] (cold) 65 nM
[calicheamicin-e] 0 - 100gM (see below)
(in MeOH) MeOH = 2.5% v/v
[T4 DNA Ligase] 10 Units/ml
[calicheamicin] moles CAL / moles CAL/ % of binding sites
jtM moles bp moles bind. sites occupieda
0 0 0 0
0.1 0-0056 0.059 2.4
0-32 0.017 0.18 7.5
1 0-056 0-59 21.4
3.2 0.17 1.8 49-8
10 0-56 5-9 78-8
32 1.7 18 92-5
100 5-6 59 97.7
Table 4.2. Estimating rate constants kI and k2 for pAS1/13m9 with 0-32 tgM
calicheamicin E.
[M(t)] =
Mo e-k t
1 + 4 Mo (1 - e-k lt) k2V
(4.30)
kl
[C(t)] 
- 4 k2
1
[Di(t)] = 2 (Mo -[C(t)]
{-kit + In LM(t)l
- [M(t)])
100
Iteration # Equation fit Fixed new value of new value of
variable kl k2
initial 4.30 [M(t)] none -2-9e-3 1.61e+3
1 4.31 [C(t)] k2 4-4e-4
2 4.32 [D(t)] kl - 2-52e+3
3 4.31 [C(t)] k2 3-77e-4
4 4.32 [D(t)] kI - 2-56e+3
5 4.31 [C(t)] k2 3-77e-4
(4.31)
(4.32)
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Figure 4.1. The cyclization and bimolecular association behavior of a 273 bp polymer of the in-phase binding site
construct. Radiolabeled polymer was mixed with cold polymer at a ratio less than 1:100. MeOH was added to a final
concentration of 2% v/v and the mixture allowed to equilibrate at 160 C. The reaction was initiated by adding T4
DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and heat-
killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by phosphorimager
analysis.
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Figure 4.2. The effect of 0.1 gM calicheamicin e on the cyclization and bimolecular association behavior of a 273 
bp
polymer of the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio 
less
than 1:100. Calicheamicin e was added and the mixture allowed to equilibrate at 160 C. The reaction was initiated 
by
adding T4 DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA 
and
heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by
phosphorimager analysis.
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Figure 4.3. The effect of 0.32 gM calicheamicin a on the cyclization and bimolecular association behavior of a 273 bp
polymer of the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less
than 1:100. Calicheamicin e was added and the mixture allowed to equilibrate at 160 C. The reaction was initiated by
adding T4 DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and
heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by
phosphorimager analysis.
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Figure 4.4. The effect of 1 gM calicheamicin e on the cyclization and bimolecular association behavior of a 273 bp
polymer of the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less
than 1:100. Calicheamicin e was added and the mixture allowed to equilibrate at 160 C. The reaction was initiated by
adding T4 DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and
heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by
phosphorimager analysis.
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Figure 4.5. The effect of 3.2 gM calicheamicin E on the cyclization and bimolecular association behavior of a 273 
bp
polymer of the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less
than 1:100. Calicheamicin e was added and the mixture allowed to equilibrate at 160 C. The reaction was initiated by
adding T4 DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA 
and
heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by
phosphorimager analysis.
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Figure 4.6.
polymer of
than 1:100.
The effect of 10 pgM calicheamicin a on the cyclization and bimolecular association behavior of a 273 bp
the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less
Calicheamicin E was added and the mixture allowed to equilibrate at 160 C. The reaction was initiated by
adding T4 DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and
heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by
phosphorimager analysis.
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Figure 4.7. The effect of 32 jiM calicheamicin E on the cyclization and bimolecular association behavior of a 273 bp
polymer of the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less
than 1:100. Calicheamicin a was added and the mixture allowed to equilibrate at 160 C. The reaction was initiated by
adding T4 DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and
heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by
phosphorimager analysis.
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Figure 4.8. The effect of 100 gM calicheamicin E on the cyclization and bimolecular association behavior of a 273 bp
polymer of the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less
than 1:100. Calicheamicin e was added and the mixture allowed to equilibrate at 16' C. The reaction was initiated by
adding T4 DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and
heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by
phosphorimager analysis.
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Figure 4.9. Reaction substrate and products versus time for the cyclization of the 273
bp polymer of the in-phase construct. Points represent empirical measurements of
the unreacted substrate, M(t), circles, C(t), and polymerized DNA, D(t). Solid lines
are plots of equations 4.30, 4.31 and 4.32 after estimates of kl and k2 have been
optimized to fit the data.
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Figure 4.10. The rate constants for cyclization and bimolecular association of the 273 bp in-phase polymer. Estimates
of kl (s-1) and k2 (M-1s -1 ) were determined for each drug concentration by optimizing the fit of equations 4.30, 4.31
and 4.32 to the data obtained from the gels shown in Figures 4.1 through 4.8 . The ring closure probability, J (Molar),
was estimated by taking the ratio of the two individual rate constants.
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Figure 4.11. The effect of calicheamicin e and its oligosaccharide on the cyclization
kinetics of the 273 bp in-phase polymer. Experiments were performed as described
previously.
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CHAPTER V
The Influence of DNA Length and Structure on the Kinetics of Bimolecular
Association
When calicheamicin E bound the DNA polymer containing drug binding sites
repeated in-phase with the helical repeat of B-DNA, the rate of unimolecular
cyclization, k1, increased while the rate of bimolecular association, k2, decreased. In
other words, at high drug concentrations the addition of calicheamicin E, or the
curvature of the DNA molecule, somehow inhibited the ability of the DNA to
dimerize. Since bimolecular association involves the joining of ends from two
different molecules, it has long been assumed that the rate of dimerization is
independent of the individual molecule's length or curvature [52]. In fact, this
assumption is a necessary prerequisite to the determination of the ring closure
probability, J, when shorter DNA molecules are used to empirically measure k2 (see
the section "Experimental Design - Measurement of Rate Constants" in Chapter IV).
Given the importance of this assumption to measuring the kinetic properties of
DNA, an experiment was designed to verify whether this indeed was the case.
Experimental Method
To rule out the possibility that the effects observed in Chapter IV were due to
a nonspecific interaction of calicheamicin E with either the DNA polymer or T4
DNA ligase, we repeated the kinetic studies with a polymer too short to cyclize (3m9
- three 21 bp repeats of the in-phase binding site construct). The short polymer
preserved the radius of curvature induced by calicheamicin bending but, because of
its reduced length, still kept the ends far apart. As a result, intramolecular
cyclization was extremely unlikely. If calicheamicin was responsible for the reduced
rate in dimerization, then this effect should be observed in the smaller DNA
molecule.
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Methods and Materials
Reagents and DNA substrates. Calicheamicin E was provided by Dr. George Ellestad
(Wyeth Ayerst Research) or synthesized as described Chapter II. All enzymes were
obtained from New England Biolabs. Deoxyoligonucleotides were prepared as
described in Chapter II.
Preparation of large quantities of a specific polymer construct. Clones containing
specific polymers were constructed, identified and amplified as described in the
Materials and Methods section of Chapter IV.
HPLC purification of pAS1 restriction fragments. GM2163 E. coli were transfected
with the appropriate plasmid containing either the 13m9 or 3m9 polymer and
grown in large quantities as described in Chapter IV. The plasmid DNA was isolated
using Qiagen Giga-Preps (Qiagen) and purified, if necessary, on CsCl gradient to
remove genomic contamination. The DNA was digested with Sap I (1 unit/pg
under standard reaction conditions), extracted once with phenol/chloroform, once
with chloroform/isoamyl alcohol and ethanol precipitated. The polymers were
purified by HPLC on a Nucleogen-DEAE 500-7 weak anion exchange column under
the following conditions:
where buffer A is 25 mM CHES, buffer B is 25 mM CHES and 1.2 M ammonium
sulfate, and the flow rate is 1 ml/min. Using this profile, 3m9, 6m9, 9m9 and 12m9
have been separated from plasmid DNA (See Figure 5.1). The appropriate peak was
collected and dialyzed repeatedly (at least four times at a 1:100 v:v ratio) against a 50-
fold dilution of TE (1 mM EDTA, 10 mM Tris-HC1 pH 7-6). The sample was then
lyophilized, resuspended in 200 pl of sterile double deionized H 20, and dialyzed
again against sterile TE. The DNA was quantified by UV absorption at 260 nm.
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Preparation of radiolabeled DNA. DNA polymers used in the cyclization
experiments were radiolabeled as described in the Materials and Methods section of
Chapter IV.
DNA cyclization reactions. The circle closure experiments were performed as
described in the Materials and Methods section of Chapter IV.
Methods of Analysis. The individual rate constants as well as the ring closure
probabilities were determined by the protocols described in the Materials and
Methods section of Chapter IV.
Results and Discussion
The effect of calicheamicin a binding on the cyclization kinetics of the 13m9
polymer suggested that somehow drug binding inhibited the ability of the DNA
molecule to form intermolecular dimers. To determine whether these results were
a response to drug interactions with T4 DNA ligase or with the DNA molecule
itself, the experiment was repeated with a DNA polymer too short to cyclize under
the identical reaction conditions.
The 3m9 DNA was prepared by cloning the appropriate plasmid (pAS1/3m9
grown in E. coli strain GM2163), isolating large quantities of the plasmid DNA,
digesting with Sap I and recovering the polymer by gel electrophoresis or HPLC.
The cyclization reactions were performed as described in the Materials and Methods
section in Chapter IV. Radiolabeled polymer was mixed with cold polymer at a ratio
less than 1:100. Calicheamicin E or MeOH was added and the mixture allowed to
equilibrate at 160 C. The reaction was initiated by adding T4 DNA ligase. At specific
time points, aliquots were removed and the reaction stopped by adding EDTA and
heat-killing the enzyme. The reaction products were then loaded directly on 4%
agarose or 4% polyacrylamide gels. Individual reaction products were identified by
non-denaturing gel electrophoresis and quantified by phosphorimager analysis as
described in Chapter III.
The results for these experiments are shown in Figures 5.2 - 5.5. Since no
circles were formed, the rate constant for bimolecular association was determined by
optimizing the fit of equation 4.36 to the experimental data. The dimerization rates
for both the 13m9 and the 3m9 polymers are shown in Figure 5.6. Unlike the 13m9
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DNA, the 3m9 does not show a significant reduction in the rate of bimolecular
association over the same drug concentrations. This rules out the possibility that
calicheamicin may be interfering with ligase activity or somehow impeding the
molecule ends from joining.
An explanation consistent with these results is that the relative proximity of
the ends of the DNA molecule affects the polymers ability to dimerize. In other
words, if the ends of the molecule are close together, they sterically interfere with
other molecules attempting to access the DNA. We could then explain the 13m9
results as follows: With no calicheamicin bound, the polymer cyclizes and
dimerizes at rates k1 and k2 respectively. At low levels of drug binding, the polymer
begins to bend. However, since only a few of the sites are bound, the overall
curvature of the molecule is relatively small and the ends remain far apart. The
rate of cyclization increases but the rate of dimerization remains unchanged. At
high concentrations of calicheamicin e a significant quantity of drug is bound. The
polymer is highly bent and the ends move close together increasing the rate of
cyclization. At the same time, however, the relative proximity of the ends inhibits
the access of other polymers attempting to dimerize, thereby reducing the rate of
dimerization. In other words, the rate of dimerization is dependent upon the
relative proximity of the ends which, in turn, is determined by the length and
curvature of the DNA. Kahn and Crothers have noted a similar change in the rate
of dimerization in a DNA molecule bent by proteins [71].
These results cause us to reconsider the theoretical model for the dimerizing
molecule. If the ends of the DNA are in close proximity (i.e., highly curved DNA),
then the rate-limiting step of the overall bimolecular association reaction is no
longer the ligation process. Instead, formation of the ligatable substrate k 12 may be
rate limiting and k21 may be greater than k12.
a b k 12  a ba b k23k 34
... . b ab a [B]
k21 ... k32 [E]
Half Ligatable Enzyme-Substrate
Molecules [H] Substrate [Sa] Complex [ES]
As a result, the expression for k2 (equation 4.23),
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Ka k34 [E0 ] (1 - fs') 2
k2 Km + [Sa]
may not be valid for highly curved DNA molecules since the equilibrium constant,
Ka, may not be independent of DNA length and curvature.
These results have serious ramifications for the calculation of kl, the rate of
cyclization, in highly curved DNA molecules. As discussed in Chapter IV, the ring
closure probability, J, can be measured directly. The rate of cyclization, kl, can then
be estimated by determining k2 in a separate reaction on a DNA substrate with ends
identical to the original but too short to cyclize and equation 4.24,
kl
J - k2
However, our results suggest that -- for highly curved DNA -- k2 in the longer DNA
is less than k2 in the shorter DNA. Therefore, estimates of kl based on
ki = J(long)-k2(short)
are larger than their actual values. This result, calls into question the cyclization
rates measured using this method.
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Figure 5.1. HPLC purification of pAS1 restriction fragments. Sap I digested
pAS1/3m9 was purified by HPLC as described in the text.
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Figure 5.2. The bimolecular association kinetics of the 63 bp polymer of the in-phase binding site construct.
Radiolabeled polymer was mixed with cold polymer at a ratio less than 1:100. MeOH was added to a final
concentration of 2% v/v and the mixture allowed to equilibrate at 160 C. The reaction was initiated by adding T4
DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and heat-
killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantified by phosphorimager
analysis.
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Figure 5.3. The effect of 4 pM calicheamicin E on the bimolecular association kinetics of a 63 bp polymer of the in-phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less than 1:100.Calicheamicin e was added and the mixture allowed to equilibriate at 160 C. The reaction was initiated by adding T4DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and heat-killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantitated by phosphorimageranalysis.
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Figure 5.4. The effect of 40 gM calicheamicin E on the bimolecular association kinetics of a 63 bp polymer of the in-
phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less than 1:100.
Calicheamicin E was added and the mixture allowed to equilibriate at 160 C.
DNA ligase. At specific time points, aliquots were removed and the reaction
killing the enzyme. Reaction products were resolved on 4% polyacrylamide
analysis.
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Figure 5.5. The effect of 400 plM calicheamicin e on the bimolecular association kinetics of a 63 
bp polymer of the in-
phase binding site construct. Radiolabeled polymer was mixed with cold polymer at a ratio less than 1:100.
Calicheamicin E was added and the mixture allowed to equilibriate at 160 C. The reaction was initiated by adding 
T4
DNA ligase. At specific time points, aliquots were removed and the reaction stopped by adding EDTA and 
heat-
killing the enzyme. Reaction products were resolved on 4% polyacrylamide gels and quantitated by phosphorimager
analysis.
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Figure 5.6. Rate of bimolecular association for the 63 and 273 bp polymers of the in-
phase DNA construct. The rate of dimerization for 63 bp polymer was determined
from the data shown in Figures 5.2 through 5.5 using equation 4.36. The rate
constant was then scaled to account for multiple reactive ends and different ligase
concentration. The rate of dimerization for 273 bp polymer was calculated as
described in Figure 4.10.
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CHAPTER VI
Determinants of Calicheamicin-Induced DNA Damage
Calicheamicin is a potent antitumor antibiotic that causes sequence-specific
oxidation of the deoxyribose of DNA [2, 7, 8, 88]. Although the drug makes several
base-specific contacts along the minor groove, the broad range of sequences bound [8,
35, 36, 43, 81] and the sensitivity of calicheamicin-induced DNA damage to base
changes outside the binding site [36, 89] suggest that sequence recognition per se is
not the primary determinant of target selection. In fact, these observations imply
that DNA structure and dynamics mediate, at least in part, the binding of
calicheamicin [31, 35, 36, 90]. The evidence presented here has shown that this is
indeed the case and that calicheamicin targets those sequences that can be easily bent
(i.e., flexible), or already exist in a conformation that optimizes the drug-DNA
interactions. This situation is analogous to that of several antibiotics that modify
DNA covalently (e.g., [44, 77, 78]).
Although seminal to the recognition process, we are not proposing that DNA
structure and dynamics are solitary determinants of calicheamicin binding. In fact, it
is clear that calicheamicin target selection is a complex process involving
electrostatic and hydrophobic interactions that are optimized by the conformational
flexibility of specific DNA sequences. In the following sections, the role of these
factors in calicheamicin target selection is discussed.
Sequence-Specific Electrostatic Interactions in Calicheamicin Binding
There is considerable evidence to suggest that the recognition of base-specific
charges within the minor groove, plays a role in the targeting of calicheamicin to
specific sequences. Figure 6.1 is a pictorial representation of the proposed hydrogen
bonding between calicheamicin and the sequence AGGAGT*ACTCCT as
determined by NMR in Dinshaw Patel's laboratory [39]. Particularly significant are
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the interactions between the thiobenzoate and thiosugar rings of the oligosaccharide
tail and the center GGA*TCC sequence. The hydrogen bonding of the thiobenzoate
iodine to the amino proton at G03 and the sulfur atom of the S-carbonyl linker to
the G04 amino proton suggest a strong affinity for the guanine dinucleotide.
Experiments replacing the 03 guanine with inosine, which lacks the 2-amino group,
have shown that disruption of this bond greatly reduces the binding of
calicheamicin [32]. In fact, a review of approximately 160 sequences, shows that a
guanine in the 5' penultimate position of the purine strand leads to reactivity 23%
of the time, which is almost 5 times the probability that a sequence without this
guanine will react. (See Appendix A for a list of the sequences analyzed and their
relative reactivities.) A sequence containing the appropriate GG*CC dinucleotide is
reactive in 50% of the cases in which it appears.
Calicheamicin also recognizes the next step on the 3' side, the 05 adenine, by
forming a hydrogen bond between the thiosugar hydroxyl and the minor groove-
facing imino group. Theoretically, this same bonding could occur between the
thiosugar and a guanine, assuming that the exocyclic amine does not sterically
interfere. It may even be possible to replace A05 with either a cytosine or thymine,
both of which have similar charges in the same relative vicinity. An identical
argument can be made for replacing the GG* CC dinucleotide with a CC* GG but both
would have to be replaced to preserve the relative orientation of charges across the
pair; especially when the propeller twist between the complementary bases is large.
3
One could imagine that this effect would be most dramatic if G04 -- alone -- were
replaced since the relationship between all three bases would be disturbed.
Two issues have emerged from this discussion. The first is that charges on
the base pairs can, and do, interact with calicheamicin. The second is that the
3 From the perspective of the minor groove, the A-T base pair looks very similar to a T-A since the
charge distribution is unchanged when the base pairs are flipped (i.e., -, -). Similarly, a G-C could
replace a C-G (i.e., -, +, -). However, when the propellor twist is high (i.e., the complementary bases
are rotated in opposite directions about an axis through the C1 atoms) the location of the positive
charges with respect to adjacent bases is altered considerably.
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relative location of these partial charges within the minor groove is critical to
ensuring that these interactions act cooperatively. Optimizing the first, requires
guanines, or possibly cytosines, at 03 and 04; and an adenine, or potentially any of
the other three bases, at 05. However, to preserve the relative positions of the partial
charges, the purine stacking should be maintained. A homopyrimidine run may
allow hydrogen bonding at 03 and 04, but not at 05. The affinity that calicheamicin
has for a wide variety of oligopurine runs may result from, at least in part, a
balancing of these requirements.
The importance of these interactions is highlighted by the finding that the
oligosaccharide tail of calicheamicin is a major contributor to the structural
perturbations induced in DNA when the drug binds (see Chapters III and IV).
These observations do not preclude other, mixed, sequences from reacting.
The suggestion here is that as the sequence deviates from the archetypal tetrapurine
run, the binding interactions are decreased and reactivity falls. However, since this
is a multi-factorial process, it is quite possible that other determinants of
calicheamicin binding mediate and reduce the significance of base-specific charge
recognition.
Shape Recognition and Hydrophobic Forces in Calicheamicin Binding
In addition to the base "sensing" properties of calicheamicin, several
experimental observations suggest that the drug is sensitive to the general
topological and hydrophobic characteristics of the recognition sequence. In addition
to hydrogen bonds with the bases, both Ikemeto et al. and Walker et al. found that
calicheamicin had substantial van der Waals associations with the nucleotides and
several hydrogen bonds with the phosphate backbone (see Figure 6.1) [27, 39].
Furthermore, assays in many labs have shown that calicheamicin-induced DNA
damage can be affected by changing the 02-15 and 01-16 base pairs in Figure 6.1;
substitutions, which according to the hydrogen bonding pattern of the bases
discussed above, should have no affect on drug binding [24, 43]. Last, binding
experiments conducted in the presence of salt have shown that hydrophobic
interactions of the drug with DNA are important mediators of DNA damage [30].
These results suggest that, in addition to specific hydrogen bonding with base
substituents, there are other forces arising from the overall conformation and
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sequence context of the binding site that play an important role in calicheamicin
target recognition.
DNA damage studies performed within our lab have shown that bases not in
direct contact with the drug can influence calicheamicin reactivity. Significantly,
having an AG*CT dinucleotide at the 5' end almost guarantees that the sequence
will be reactive. In sequences beginning with an AG*CT, 7 of 8 were damaged by
calicheamicin. The exception was AGCCAA which contains a substantial disruption
of the oligopurine tract. The lack of a 5' adenine appears to be partially overcome
when the 5' penultimate base is a guanine, but only in a few cases. In fact, only 1 out
of 7 sequences beginning with GG*CC were damaged by calicheamicin while no
TG*CA or CG*CG beginning sequences were damaged (0/6 and 0/13 respectively).
Therefore, a purine (adenine more than guanine) at the 5' end of the sequence
stabilizes the binding of calicheamicin to the minor groove. (The guanine may be
less desirable becuase the exocyclic amine may sterically interfere with the
positioning of the rhamnose sugar ring.)
It is possible that the 5' purine reinforces a helical conformation within the
binding site that enhances its affinity for calicheamicin. This may occur if the base
contributes to the presence and maintenance of a high degree of propeller twist
throughout the oligosaccharide binding region and/or prevents a helical
transformation upon dehydration [91]. High levels of propeller twist, known to exist
in A-tracts, may expose a greater proportion of the lipophilic base surfaces to the
oligosaccharide tail of calicheamicin. This stacking arrangement may cause a
narrowing of the minor groove, increasing van der Waals interactions and
promoting hydrogen bonding between calicheamicin and the phosphate backbone.
It is important to note, however, that a terminal adenine does not -- by itself --
define a calicheamicin binding site since sequences beginning with an adenine
followed thymine or cytosine are almost always unreactive.
As mentioned earlier, hydrophobic forces have been shown to be important
contributors to the overall binding energy of calicheamicin to DNA. This may
explain the generally greater affinity of calicheamicin for homopurine tracts rather
than mixed sequence DNA. Since homopurine sequences are more hydrated [92],
the increased displacement of water may make drug binding entropically more
favorable.
These data suggest that the topological and thermodynamic features of the
binding site sequence are likely to contribute along with the base-sensing properties
of calicheamicin to determine site selectivity.
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DNA Structure and Dynamics
Calicheamicin bends DNA when it binds. Therefore, sequences that can most
easily adopt the conformation of the drug-DNA complex are likely energetically
favorable targets for binding. However, it is not clear where in the sequence this
element of flexibility occurs.
As discussed in Chapter I and shown in Appendix A, calicheamicin damages
DNA most frequently at the 3' end of homopurine runs. A closer investigation of
target sequences shows that the amount of damage is sensitive to base substitutions
all the way up to the 07 position. For example, we have seen that the sequence
AGGGTC gets damaged 40% more often than the sequence AGGGTG where the only
difference between the two is the 07 base pair which is two bases away from the
putative drug binding site. Since the results of the experiments described in
Chapters III and IV suggest that calicheamicin binding sites contain some element of
flexibility, and further, since the 07 base pair has no contact with the drug, we
propose that the ability of the binding site to alter its conformation in response to
drug binding occurs as a result of, and near to, the 3' end of the sequence.
Theoretical and empirical evidence suggests that the sugar-phosphate
backbones of DNA are relatively flexible and that, while they constrain the bases to a
small region of conformational space, they play essentially no role in determining
the sequence-dependent structure [93, 94]. As a result, bending is primarily a
function of the base-to-base stacking interactions. Since calicheamicin appears to
prefer sequences that can be most easily bent, we hypothesize that the drug targets
those sequences which can most easily adopt a conformation that could lead to
bending of the helical axis. In other words, the drug favors a conformational state
that is not often observed naturally, but can exist when supported by other intrinsic
or extrinsic forces. Of the six degrees of freedom that each base pair has relative to its
neighbor (three translations and three rotations about orthogonal axes through the
center of the base-pair), roll is considered to be the motion responsible for bending of
the helical axis [45]. Therefore, we posit that the bending observed when
calicheamicin binds DNA is the result of a change in one, or more, of the individual
roll angles at the 3' end of the oligopurine tract. We further suggest that the drug
assists this deformation by reinforcing a high degree of propeller twist throughout
the oligopurine tract and widening the minor groove at the site of aglycone binding.
127
Roll between base-pairs can occur in response to the individual forces
mediating the location of one base-pair with respect to another. The classical
example, is the highly propeller twisted pyrimidine-purine step, shown below [45].
twist
slide G roll
5' 3'
Using the block notation introduced by Calladine & Drew [95], the
figure portrays a CG step as seen from the minor groove. The
directions of positive slide, roll and twist are shown. Negative
propeller twist leads to a cross-strand steric clash between the purines
in the major groove (asterisk).
To avoid a steric clash between purines in the minor groove, the 3' base can decrease
the propeller twist, reduce its twist angle with respect to the 5' base, slide in either a
positive or negative direction, or roll towards the major groove (positive) [96]. The
motions are coupled. For example, in this case a negative slide would cause the
purines to overlap forcing them to roll such that their surfaces were parallel to one
another. This conformation is not only favored sterically, but it also maximizes the
favorable hydrophobic and electrostatic interactions [95].
Figure 6.2 is a slide/roll map for each of the possible dinucleotide steps created
by Christopher Hunter [95]. Each dinucleotide is plotted in a location that
corresponds to the position of the bases that minimizes the unfavorable electrostatic
and steric forces acting between them. Interestingly, purine-purine steps are -- for
the most part -- comfortable at near zero slide and roll. This is consistent with a
model in which the oligopurine tract forms a stable B-DNA type structure. Many of
the purine-pyrimidine steps, however, are not comfortable in a zero-slide/zero-roll
conformation. In particular, the AT, AC and GT dinucleotides all prefer a similar
negative-slide/negative-roll conformation. This is primarily due to a steric clash
between the thymine methyl group and the 1' carbon at of the 5' neighboring sugar.
It may be, that calicheamicin binding encourages a base slide at dinucleotide steps
that are comfortable assuming a high negative slide conformation. The result
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would be the introduction of a localized roll possibly leading to bending of the
helical axis.
The above rationale appears consistent with both the observed bending and
the site selectivity of calicheamicin. Calicheamicin-induced DNA damage occurs
predominantly at the 3' ends of oligopurine runs. A wide variety of sequences can
facilitate binding but almost all of the most reactive sites contain an AT, AC or GT
base step at the 3' end. A review of the damage sequences in Appendix A, shows
that this step can occur between 06 and 07, 05 and 06, and even 04 and 05 positions.
An explanation for this variability might be that the slide can occur in either the 05,
06 or 07 steps. In fact, it may be the positioning of the aglycone between the
phosphate backbones at T07 and C13 that encourages this movement. NMR studies
by Ikemeto et al. [39] have shown that the minor groove widens at this site; a
deformation that might facilatate negative sliding of the base pairs somewhere
between 04 and 07.
Calicheamicin Binding to DNA
The data here and elsewhere, suggest that calicheamicin target selection is a
result of the electrostatic, hydrophobic and structural properties of the target
sequence. It is the optimization of these factors that dictates where, and how often, a
specific DNA molecule is damaged. It is important to understand that these forces
need not be individually optimized to ensure drug binding. A sequence may be
more appropriate in one sense than another but still confer enough of an advantage
over an adjacent sequence to make it a target for calicheamicin. As a result of this
heterogeneity, we should expect to see a variety of sequences that serve as suitable
binding substrates for the drug. Indeed, this is the case.
Our addition to this model has been to establish the role of DNA structure
and dynamics in the target recognition process. We have shown that two different
high-affinity calicheamicin binding sites are not significantly curved and that when
calicheamicin binds to these sequences it bends, and possibly twists, the helix. These
results suggest that -- in general -- calicheamicin binding sites are not curved, but are
instead flexible DNA sequences that can be easily bent or "trapped" in a
conformation that fosters equilibrium drug binding. In addition, these findings
imply that sequences already curved or bent into the drug-bound conformation
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would also be energetically favorable targets since they do not need to be forced into
a bent conformation.
A structure and dynamics based paradigm for calicheamicin target
recognition explains why, as discussed earlier, calicheamicin-induced DNA damage
is influenced by the sequence context and overall topology of the binding site. Since
calicheamicin binding depends on DNA flexibility, adjacent bases can affect drug
binding by changing the dynamic behavior of the target sequence; an effect that may
extend for several base pairs [79, 80]. In contrast, changes in DNA topology must
precisely match the desired drug-bound conformation to facilitate drug binding. For
example, in the nucleosome studies described in Chapter I [43, 97], DNA bending
reduced or had no effect on calicheamicin-induced DNA damage except at one site.
This is consistent with our suggestion that calicheamicin does not target curved or
bent DNA indiscriminately but instead, binds only those sequences bent into a
specific conformation.
electrostatics hydrophobic
interactions
conformational
flexibility
Although DNA structure and dynamics are seminal to drug binding,
calicheamicin target selection is a complex process involving several interactions
that are optimized -- not necessarily controlled -- by the conformational flexibility of
specific DNA sequences. In all cases a balance must be achieved between the DNA's
intrinsic resistance to movement and those forces -- electrostatic and hydrophobic --
that bind calicheamicin to DNA. In fact, the above discussion suggests that
calicheamicin targets the 3' ends of homopurine runs as a result of their unique
thermodynamic and structural properties.
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Appendix A
A Compendium of Calicheamicin Binding Sites
DNA sequences damaged by calicheamicin 711 are listed below with references
stating where the studies were performed. For each site, the six base pairs
preceeding 4' hydrogen abstraction -- going 5' to 3'-- are listed.
aglycone 5'-hydrogen 
abstracted
X X X Py Py Py Py X 
X 3'
minor
groove
3' X X X Pu Pu Pu Pu X X 5
listed sequence
4'-hydrogen abstracted 4
When possible,- relative damage intensities are assigned.
Damage Sequences and Relative Damage Intensities
Yu, L., A. A. Salzberg, et al. (1995). "New insights into calicheamicin-DNA
interactions derived from a model nucleosome system." Bioorg. Med. Chem. 3(6):
729-741.
Sequence Damage Sequence Damage Sequence Damage Sequence Damage
CCACCC 0 CACCCT 0 ACCCTG 0 CCCTGA 0
CCTGAA 0 CTGAAA 0 AGTGCC 3 GTGCCC 0
TGCCCG 0 GCCCGA 0 CCCGAT 0 CGATAT 0
ATATCG 0 TCGTCT 0 CGTCTG 0 GTCTGA 0
TGATCT 0 GATCTC 0 ATCTCG 0 TCTCGG 0
CTCGGA 0 TCGGAA 0 GGAAGC 4 GAAGCC 0
AAGCCA 0 AGCCAA 0 GCCAAG 0 CCAAGC 0
CAAGCA 0 AAGCAG 0 GCAGGG 0 CAGGGT 0
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AGGGTC
CGGGCC
CTGGTT
AGTACT
TACTAA
ACCAGG
GGCCCG
GACCCT
CTGCTT
TTGGCT
TCCGAG
AGATCA
CAGACG
ATATCG
ACTTTC
TCAGGG
GGGTCG
GGGCCT
GGTTAG
GTACTT
CTAACC
CCAGGC
GCCCGA
ACCCTG
TGCTTG
GCTTCC
CCGAGA
GATCAG
GACGAT
TATCGG
CTTTCA
CAGGGT
GGTCGG
GGCCTG
GTTAGT
AGTACT
TAACCA
CAGGCC
CCCGAC
CCCTGC
GCTTGG
CTTCCG
CGAGAT
ATCAGA
ACGATA
ATCGGG
TTTCAG
AGGGTG
GTCGGG
CCTGGT
TAGTAC
GTACTA
AACCAG
AGGCCC
CGACCC
CCTGCT
CTTGGC
TTCCGA
GAGATC
TCAGAC
CGATAT
TCGGGC
TTCAGG
XXXXXX
Mah, S. C., M. A. Price, et al. (1994). "Features of DNA recognition for oriented
binding and cleavage by calicheamicin." Tetrahedron 50(5): 1361-1378.
Sequence Damage
CGCCAG
GGGTTT
TTTCCC
CCAGTC
TCACGA
ACGTTG
TGTAAA
AAACGA
GACGGC
TCGTTT
TTTACA
CAACGT
GTCGTG
TGACTG
TGGGAA
AAACCC
Sequence Damage Sequence Damage Sequence Damage
GCCAGG
GGTTTT
TTCCCA
CAGTCA
CACGAC
CGTTGT
GTAAAA
AACGAC
GCCGTC
CGTTTT
TTACAA
AACGTC
TCGTGA
GACTGG
GGGAAA
AACCCT
CCAGGG
GTTTTC
TCCCAG
AGTCAC
ACGACG
GTTGTA
TAAAAC
ACGACG
CCGTCG
GTTTTA
TACAAC
ACGTCG
CGTGAC
ACTGGG
GGAAAA
ACCCTG
CAGGGT
TTTTCC
CCCAGT
GTCACG
CGACGT
TTGTAA
AAAACG
CGACGG
CGTCGT
TTTTAC
ACAACG
CGTCGT
GTGACT
CTGGGA
AAAACC
CCCTGG
Additional Sequences Damaged by Calicheamicin
AGGAAT
AAAACG
AGGTTG
TGAATT
AGGAAC AGGAGT
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Sequence
AGGATT
AGGACA
AAAACC
AGGACT
Reference
[11
[2]
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